train.jsonl

{"record_id": "NTR-001", "dataset": "nootropics", "entry_type": "compound", "name": "Piracetam", "category": "racetam", "goal": null, "mechanisms": ["AMPA receptor potentiation", "Increased acetylcholine turnover", "Membrane fluidity enhancement", "Mitochondrial function improvement", "NMDA receptor modulation"], "primary_effects": ["memory consolidation", "verbal learning", "cognitive processing speed", "neuroprotection"], "dosing_summary": "{\"administration\": [\"oral\"], \"bioavailability_percent\": 100, \"frequency\": \"2-3x per day\", \"half_life_hours\": 5, \"high\": \"4800-9600mg/day\", \"onset_minutes\": 30, \"standard\": \"1600-4800mg/day\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"severe renal impairment\", \"hemorrhagic stroke\"], \"drug_interactions\": [\"potentiates stimulants\", \"anticoagulants (slight)\"], \"pregnancy\": \"avoid — insufficient data\", \"side_effects\": [\"headache (choline deficiency)\", \"brain fog at low choline\", \"insomnia if taken late\", \"irritability\"], \"tolerance\": \"minimal\", \"toxicity\": \"very low — LD50 >10g/kg in rodents\"}", "evidence_level": "moderate", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"7491-74-9\", \"category\": \"racetam\", \"choline_note\": \"Always stack with choline source (Alpha-GPC or CDP-choline) to prevent headaches and potentiate effects\", \"choline_requirement\": \"mandatory\", \"clinical_evidence\": {\"level\": \"moderate\", \"pubmed_ids\": [\"6135678\", \"9152205\", \"11139086\"], \"studies\": [\"Alzheimer's research (mixed)\", \"aphasia improvement\", \"cognitive aging\", \"alcoholic cognitive deficit\"]}, \"cost_per_month_usd\": 15, \"dosing\": {\"administration\": [\"oral\"], \"bioavailability_percent\": 100, \"frequency\": \"2-3x per day\", \"half_life_hours\": 5, \"high\": \"4800-9600mg/day\", \"onset_minutes\": 30, \"standard\": \"1600-4800mg/day\"}, \"id\": \"NTR-001\", \"legal_status\": {\"CA\": \"unscheduled\", \"EU\": \"prescription in UK, OTC elsewhere\", \"US\": \"unscheduled, not FDA approved\"}, \"mechanisms\": [\"AMPA receptor potentiation\", \"Increased acetylcholine turnover\", \"Membrane fluidity enhancement\", \"Mitochondrial function improvement\", \"NMDA receptor modulation\"], \"molecular_formula\": \"C6H10N2O2\", \"molecular_weight\": 142.16, \"name\": \"Piracetam\", \"notes\": \"The original racetam. Good baseline. Effects subtle but real at high doses. Foundational compound.\", \"primary_effects\": [\"memory consolidation\", \"verbal learning\", \"cognitive processing speed\", \"neuroprotection\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"severe renal impairment\", \"hemorrhagic stroke\"], \"drug_interactions\": [\"potentiates stimulants\", \"anticoagulants (slight)\"], \"pregnancy\": \"avoid — insufficient data\", \"side_effects\": [\"headache (choline deficiency)\", \"brain fog at low choline\", \"insomnia if taken late\", \"irritability\"], \"tolerance\": \"minimal\", \"toxicity\": \"very low — LD50 >10g/kg in rodents\"}, \"source\": [\"synthesis\", \"online vendors\"], \"synergistic_stacks\": [{\"compound\": \"Alpha-GPC\", \"effect\": \"enhanced cognition, headache prevention\", \"ratio\": \"4:1 piracetam:alpha-gpc\"}, {\"compound\": \"Aniracetam\", \"effect\": \"mood + memory combo\", \"ratio\": \"variable\"}, {\"compound\": \"Oxiracetam\", \"effect\": \"logic + memory stack\", \"ratio\": \"variable\"}]}"}
{"record_id": "NTR-002", "dataset": "nootropics", "entry_type": "compound", "name": "Aniracetam", "category": "racetam", "goal": null, "mechanisms": ["AMPA receptor positive allosteric modulator", "mGluR1/5 agonism", "D2/D3 dopamine modulation", "5-HT2A serotonin modulation", "Acetylcholine release enhancement"], "primary_effects": ["anxiety reduction", "holistic/creative thinking", "mood enhancement", "verbal fluency", "memory"], "dosing_summary": "{\"administration\": [\"oral\"], \"bioavailability_percent\": 15, \"fat_soluble\": true, \"frequency\": \"2x per day\", \"half_life_hours\": 1.5, \"high\": \"1500-3000mg/day\", \"note\": \"MUST be taken with fat for absorption\", \"onset_minutes\": 20, \"standard\": \"750-1500mg/day\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"known hypersensitivity\"], \"drug_interactions\": [\"potentiates alcohol\"], \"side_effects\": [\"headache (choline deficiency)\", \"digestive upset\", \"irritability\"], \"tolerance\": \"low\", \"toxicity\": \"very low\"}", "evidence_level": "moderate", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"72432-10-1\", \"category\": \"racetam\", \"choline_requirement\": \"recommended\", \"clinical_evidence\": {\"level\": \"moderate\", \"pubmed_ids\": [\"1794001\", \"11515981\"], \"studies\": [\"anxiety disorders\", \"ADHD adjunct\", \"cognitive aging\", \"stroke rehabilitation\"]}, \"cost_per_month_usd\": 20, \"dosing\": {\"administration\": [\"oral\"], \"bioavailability_percent\": 15, \"fat_soluble\": true, \"frequency\": \"2x per day\", \"half_life_hours\": 1.5, \"high\": \"1500-3000mg/day\", \"note\": \"MUST be taken with fat for absorption\", \"onset_minutes\": 20, \"standard\": \"750-1500mg/day\"}, \"id\": \"NTR-002\", \"legal_status\": {\"CA\": \"unscheduled\", \"EU\": \"varies by country\", \"US\": \"unscheduled\"}, \"mechanisms\": [\"AMPA receptor positive allosteric modulator\", \"mGluR1/5 agonism\", \"D2/D3 dopamine modulation\", \"5-HT2A serotonin modulation\", \"Acetylcholine release enhancement\"], \"molecular_formula\": \"C12H13NO3\", \"molecular_weight\": 219.24, \"name\": \"Aniracetam\", \"notes\": \"Best racetam for mood/anxiety + cognition. Popular in creative fields. Short half-life requires multiple doses.\", \"primary_effects\": [\"anxiety reduction\", \"holistic/creative thinking\", \"mood enhancement\", \"verbal fluency\", \"memory\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"known hypersensitivity\"], \"drug_interactions\": [\"potentiates alcohol\"], \"side_effects\": [\"headache (choline deficiency)\", \"digestive upset\", \"irritability\"], \"tolerance\": \"low\", \"toxicity\": \"very low\"}, \"synergistic_stacks\": [{\"compound\": \"Alpha-GPC\", \"effect\": \"full cognitive suite\", \"ratio\": \"750mg ani : 300mg alpha-gpc\"}, {\"compound\": \"Oxiracetam\", \"effect\": \"PAO stack — holistic + logical\", \"ratio\": \"1:1\"}, {\"compound\": \"Piracetam\", \"effect\": \"classic stack\", \"ratio\": \"1:4\"}]}"}
{"record_id": "NTR-003", "dataset": "nootropics", "entry_type": "compound", "name": "Alpha-GPC", "category": "cholinergic", "goal": null, "mechanisms": ["Direct acetylcholine precursor", "Crosses blood-brain barrier efficiently", "Growth hormone secretagogue (IV)", "Neuroprotective via membrane phosphatidylcholine"], "primary_effects": ["focus", "working memory", "power output", "racetam potentiation", "GH pulse"], "dosing_summary": "{\"administration\": [\"oral\", \"IV (clinical)\"], \"bioavailability_percent\": 40, \"frequency\": \"1-2x per day\", \"half_life_hours\": 4, \"high\": \"600-1200mg/day\", \"onset_minutes\": 45, \"standard\": \"300-600mg/day\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"caution in bipolar disorder\"], \"drug_interactions\": [\"scopolamine antagonism\", \"anticholinergics\"], \"side_effects\": [\"headache at high doses\", \"depression (rare)\", \"fatigue\", \"GI upset\"], \"tolerance\": \"none\", \"toxicity\": \"very low\"}", "evidence_level": "strong", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"28319-77-9\", \"category\": \"cholinergic\", \"clinical_evidence\": {\"level\": \"strong\", \"pubmed_ids\": [\"12637119\", \"10847474\"], \"studies\": [\"Alzheimer's disease\", \"stroke recovery\", \"age-related cognitive decline\", \"athletic performance\"]}, \"cost_per_month_usd\": 25, \"dosing\": {\"administration\": [\"oral\", \"IV (clinical)\"], \"bioavailability_percent\": 40, \"frequency\": \"1-2x per day\", \"half_life_hours\": 4, \"high\": \"600-1200mg/day\", \"onset_minutes\": 45, \"standard\": \"300-600mg/day\"}, \"id\": \"NTR-003\", \"legal_status\": {\"CA\": \"NHP\", \"EU\": \"food supplement\", \"US\": \"dietary supplement\"}, \"mechanisms\": [\"Direct acetylcholine precursor\", \"Crosses blood-brain barrier efficiently\", \"Growth hormone secretagogue (IV)\", \"Neuroprotective via membrane phosphatidylcholine\"], \"molecular_formula\": \"C8H20NO6P\", \"molecular_weight\": 257.22, \"name\": \"Alpha-GPC\", \"notes\": \"Best choline source for CNS. Superior BBB penetration vs choline bitartrate. Essential companion for racetams.\", \"primary_effects\": [\"focus\", \"working memory\", \"power output\", \"racetam potentiation\", \"GH pulse\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"caution in bipolar disorder\"], \"drug_interactions\": [\"scopolamine antagonism\", \"anticholinergics\"], \"side_effects\": [\"headache at high doses\", \"depression (rare)\", \"fatigue\", \"GI upset\"], \"tolerance\": \"none\", \"toxicity\": \"very low\"}, \"synergistic_stacks\": [{\"compound\": \"any racetam\", \"effect\": \"essential choline source\"}, {\"compound\": \"Huperzine-A\", \"effect\": \"acetylcholine maximization — use cautiously\"}, {\"compound\": \"caffeine+theanine\", \"effect\": \"clean focus stack\"}]}"}
{"record_id": "NTR-004", "dataset": "nootropics", "entry_type": "compound", "name": "Modafinil", "category": "eugeroic", "goal": null, "mechanisms": ["Dopamine reuptake inhibition (DAT)", "Norepinephrine reuptake inhibition", "Orexin/hypocretin system activation", "Histamine H3 receptor antagonism", "Glutamate enhancement, GABA reduction"], "primary_effects": ["wakefulness", "executive function", "working memory", "motivation", "fatigue resistance"], "dosing_summary": "{\"administration\": [\"oral\"], \"bioavailability_percent\": 80, \"frequency\": \"once per day (morning)\", \"half_life_hours\": 12, \"high\": \"200-400mg/day\", \"onset_minutes\": 60, \"standard\": \"100-200mg/day\"}", "safety_summary": "{\"addiction_potential\": \"low — much lower than traditional stimulants\", \"contraindications\": [\"hypersensitivity\", \"left ventricular hypertrophy\", \"Tourette syndrome\"], \"drug_interactions\": [\"CYP3A4 inducer — reduces hormonal contraceptives efficacy\", \"cyclosporine\", \"steroidal contraceptives\"], \"side_effects\": [\"insomnia\", \"headache\", \"nausea\", \"anxiety\", \"appetite suppression\", \"skin reactions (rare SJS)\"], \"tolerance\": \"mild with chronic use\", \"toxicity\": \"low\"}", "evidence_level": "strong", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"68693-11-8\", \"category\": \"eugeroic\", \"clinical_evidence\": {\"level\": \"strong\", \"pubmed_ids\": [\"12190820\", \"11014561\", \"22736596\"], \"studies\": [\"narcolepsy (FDA approved)\", \"shift work disorder\", \"military cognitive performance\", \"ADHD adjunct\"]}, \"cost_per_month_usd\": 30, \"dosing\": {\"administration\": [\"oral\"], \"bioavailability_percent\": 80, \"frequency\": \"once per day (morning)\", \"half_life_hours\": 12, \"high\": \"200-400mg/day\", \"onset_minutes\": 60, \"standard\": \"100-200mg/day\"}, \"id\": \"NTR-004\", \"legal_status\": {\"CA\": \"Schedule F prescription\", \"EU\": \"prescription only\", \"FR\": \"ordonnance sécurisée\", \"US\": \"Schedule IV prescription\"}, \"mechanisms\": [\"Dopamine reuptake inhibition (DAT)\", \"Norepinephrine reuptake inhibition\", \"Orexin/hypocretin system activation\", \"Histamine H3 receptor antagonism\", \"Glutamate enhancement, GABA reduction\"], \"molecular_formula\": \"C15H15NO2S\", \"molecular_weight\": 273.35, \"name\": \"Modafinil\", \"notes\": \"Gold standard for wakefulness and executive function. Non-stimulant mechanism. Avoid daily use to prevent tolerance. Excellent for shift work and demanding cognitive tasks.\", \"primary_effects\": [\"wakefulness\", \"executive function\", \"working memory\", \"motivation\", \"fatigue resistance\"], \"safety\": {\"addiction_potential\": \"low — much lower than traditional stimulants\", \"contraindications\": [\"hypersensitivity\", \"left ventricular hypertrophy\", \"Tourette syndrome\"], \"drug_interactions\": [\"CYP3A4 inducer — reduces hormonal contraceptives efficacy\", \"cyclosporine\", \"steroidal contraceptives\"], \"side_effects\": [\"insomnia\", \"headache\", \"nausea\", \"anxiety\", \"appetite suppression\", \"skin reactions (rare SJS)\"], \"tolerance\": \"mild with chronic use\", \"toxicity\": \"low\"}, \"synergistic_stacks\": [{\"compound\": \"Alpha-GPC\", \"effect\": \"sustained focus + memory\"}, {\"compound\": \"L-theanine\", \"effect\": \"reduces jitteriness\"}, {\"compound\": \"Racetams\", \"effect\": \"cognitive enhancement stack\"}]}"}
{"record_id": "NTR-005", "dataset": "nootropics", "entry_type": "compound", "name": "Lion's Mane (Hericium erinaceus)", "category": "natural", "goal": null, "mechanisms": ["NGF (Nerve Growth Factor) stimulation via hericenones", "BDNF upregulation", "Myelination support via erinacines (cross BBB)", "Anti-neuroinflammation", "Gut-brain axis modulation"], "primary_effects": ["neurogenesis", "memory long-term", "anxiety reduction", "nerve regeneration", "gut health"], "dosing_summary": "{\"administration\": [\"oral\"], \"form_note\": \"Fruiting body extract > mycelium. Look for >30% beta-glucans, confirmed erinacines content.\", \"frequency\": \"1-2x per day\", \"high\": \"1000-3000mg/day\", \"onset_days\": 14, \"peak_effect_weeks\": 8, \"standard\": \"500-1000mg/day\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"mushroom allergy\", \"autoimmune (theoretical — immunomodulatory)\"], \"drug_interactions\": [\"anticoagulants (theoretical)\", \"immunosuppressants (caution)\"], \"side_effects\": [\"GI discomfort (rare)\", \"allergy (mushroom sensitive)\", \"mild stimulation\"], \"tolerance\": \"none\", \"toxicity\": \"very low — centuries of culinary use\"}", "evidence_level": "moderate (human) + strong (animal)", "source_file": "nootropics/nootropics_database.json", "raw": "{\"active_compounds\": [\"hericenones\", \"erinacines\", \"beta-glucans\"], \"cas_number\": \"N/A (mushroom extract)\", \"category\": \"natural\", \"clinical_evidence\": {\"level\": \"moderate (human) + strong (animal)\", \"pubmed_ids\": [\"18844328\", \"23735479\", \"31413172\"], \"studies\": [\"MCI improvement 2009 Mori\", \"anxiety/depression\", \"peripheral nerve regeneration\", \"gut microbiome\"]}, \"cost_per_month_usd\": 30, \"dosing\": {\"administration\": [\"oral\"], \"form_note\": \"Fruiting body extract > mycelium. Look for >30% beta-glucans, confirmed erinacines content.\", \"frequency\": \"1-2x per day\", \"high\": \"1000-3000mg/day\", \"onset_days\": 14, \"peak_effect_weeks\": 8, \"standard\": \"500-1000mg/day\"}, \"id\": \"NTR-005\", \"legal_status\": {\"CA\": \"NHP\", \"EU\": \"novel food (extract), food supplement\", \"US\": \"dietary supplement\"}, \"mechanisms\": [\"NGF (Nerve Growth Factor) stimulation via hericenones\", \"BDNF upregulation\", \"Myelination support via erinacines (cross BBB)\", \"Anti-neuroinflammation\", \"Gut-brain axis modulation\"], \"name\": \"Lion's Mane (Hericium erinaceus)\", \"notes\": \"Only nootropic with credible neurogenesis evidence in humans. Long-term compound — 8+ weeks for full effect. Quality varies enormously between products.\", \"primary_effects\": [\"neurogenesis\", \"memory long-term\", \"anxiety reduction\", \"nerve regeneration\", \"gut health\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"mushroom allergy\", \"autoimmune (theoretical — immunomodulatory)\"], \"drug_interactions\": [\"anticoagulants (theoretical)\", \"immunosuppressants (caution)\"], \"side_effects\": [\"GI discomfort (rare)\", \"allergy (mushroom sensitive)\", \"mild stimulation\"], \"tolerance\": \"none\", \"toxicity\": \"very low — centuries of culinary use\"}, \"synergistic_stacks\": [{\"compound\": \"Bacopa Monnieri\", \"effect\": \"memory consolidation + neurogenesis\"}, {\"compound\": \"Ashwagandha\", \"effect\": \"stress resilience + cognitive protection\"}, {\"compound\": \"Reishi\", \"effect\": \"immune + neuro support combo\"}]}"}
{"record_id": "NTR-006", "dataset": "nootropics", "entry_type": "compound", "name": "Bacopa Monnieri", "category": "adaptogen", "goal": null, "mechanisms": ["Protein kinase C activation in hippocampus", "Dendrite branching enhancement", "Acetylcholinesterase inhibition (mild)", "MAO inhibition (mild)", "Antioxidant — reduces lipid peroxidation", "Cortisol modulation"], "primary_effects": ["memory consolidation", "learning speed", "anxiety reduction", "neuroprotection"], "dosing_summary": "{\"administration\": [\"oral\"], \"fat_soluble\": true, \"frequency\": \"once per day with fat\", \"onset_weeks\": 4, \"peak_effect_weeks\": 12, \"standard\": \"300-450mg/day (45% bacosides)\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"thyroid disorders (may reduce T4)\", \"bradycardia\"], \"drug_interactions\": [\"thyroid medications\", \"sedatives (additive)\", \"CYP450 interactions\"], \"side_effects\": [\"nausea\", \"GI cramping\", \"dry mouth\", \"fatigue early on\"], \"tolerance\": \"none\", \"toxicity\": \"very low\"}", "evidence_level": "strong — multiple RCTs", "source_file": "nootropics/nootropics_database.json", "raw": "{\"active_compounds\": [\"bacosides A & B\", \"bacopasaponins\", \"alkaloids\"], \"cas_number\": \"93164-91-1 (bacosides)\", \"category\": \"adaptogen\", \"clinical_evidence\": {\"level\": \"strong — multiple RCTs\", \"pubmed_ids\": [\"12093601\", \"22747190\", \"16401645\"], \"studies\": [\"memory in elderly (multiple)\", \"ADHD children\", \"anxiety\", \"cognitive aging\"]}, \"cost_per_month_usd\": 15, \"dosing\": {\"administration\": [\"oral\"], \"fat_soluble\": true, \"frequency\": \"once per day with fat\", \"onset_weeks\": 4, \"peak_effect_weeks\": 12, \"standard\": \"300-450mg/day (45% bacosides)\"}, \"id\": \"NTR-006\", \"legal_status\": {\"EU\": \"food supplement\", \"IN\": \"traditional Ayurvedic medicine\", \"US\": \"dietary supplement\"}, \"mechanisms\": [\"Protein kinase C activation in hippocampus\", \"Dendrite branching enhancement\", \"Acetylcholinesterase inhibition (mild)\", \"MAO inhibition (mild)\", \"Antioxidant — reduces lipid peroxidation\", \"Cortisol modulation\"], \"name\": \"Bacopa Monnieri\", \"notes\": \"Best studied natural nootropic for memory. Effect is cumulative — don't judge in first 2 weeks. Nausea common early, take with food.\", \"primary_effects\": [\"memory consolidation\", \"learning speed\", \"anxiety reduction\", \"neuroprotection\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"thyroid disorders (may reduce T4)\", \"bradycardia\"], \"drug_interactions\": [\"thyroid medications\", \"sedatives (additive)\", \"CYP450 interactions\"], \"side_effects\": [\"nausea\", \"GI cramping\", \"dry mouth\", \"fatigue early on\"], \"tolerance\": \"none\", \"toxicity\": \"very low\"}, \"synergistic_stacks\": [{\"compound\": \"Lion's Mane\", \"effect\": \"memory + neurogenesis\"}, {\"compound\": \"Ashwagandha\", \"effect\": \"stress + memory stack\"}, {\"compound\": \"Ginkgo Biloba\", \"effect\": \"circulation + memory\"}]}"}
{"record_id": "NTR-007", "dataset": "nootropics", "entry_type": "compound", "name": "Semax", "category": "peptide", "goal": null, "mechanisms": ["BDNF and NGF upregulation", "Melanocortin receptor modulation (MC4R)", "Dopamine and serotonin modulation", "Anti-neuroinflammatory", "Neuroprotection via oxidative stress reduction"], "primary_effects": ["executive function", "working memory", "motivation", "ADHD symptoms", "neuroprotection", "stroke rehabilitation"], "dosing_summary": "{\"administration\": [\"intranasal (preferred)\", \"subcutaneous\"], \"cycle\": \"typically 2 weeks on, 2 weeks off\", \"frequency\": \"1-2x per day\", \"half_life_minutes\": 20, \"high\": \"600-900mcg/day\", \"onset_minutes\": 15, \"standard\": \"300-600mcg/day\"}", "safety_summary": "{\"addiction_potential\": \"low\", \"contraindications\": [\"mental health conditions (BDNF implications)\", \"epilepsy\"], \"drug_interactions\": [\"limited data\"], \"side_effects\": [\"nasal irritation\", \"mild anxiety at high doses\", \"fatigue post-cycle\"], \"tolerance\": \"mild with extended use\", \"toxicity\": \"very low\"}", "evidence_level": "moderate (Russian clinical data)", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"80714-61-0\", \"category\": \"peptide\", \"clinical_evidence\": {\"level\": \"moderate (Russian clinical data)\", \"pubmed_ids\": [\"17017912\", \"11396316\"], \"studies\": [\"ADHD children (Russia)\", \"stroke recovery\", \"cognitive aging\", \"optic nerve disease\"]}, \"cost_per_month_usd\": 40, \"dosing\": {\"administration\": [\"intranasal (preferred)\", \"subcutaneous\"], \"cycle\": \"typically 2 weeks on, 2 weeks off\", \"frequency\": \"1-2x per day\", \"half_life_minutes\": 20, \"high\": \"600-900mcg/day\", \"onset_minutes\": 15, \"standard\": \"300-600mcg/day\"}, \"id\": \"NTR-007\", \"legal_status\": {\"EU\": \"gray market\", \"RU\": \"approved drug (nasal spray)\", \"US\": \"not FDA approved, gray market\"}, \"mechanisms\": [\"BDNF and NGF upregulation\", \"Melanocortin receptor modulation (MC4R)\", \"Dopamine and serotonin modulation\", \"Anti-neuroinflammatory\", \"Neuroprotection via oxidative stress reduction\"], \"molecular_formula\": \"C37H51N9O10S\", \"name\": \"Semax\", \"notes\": \"Underrated peptide with strong evidence base (mostly Russian). Intranasal is convenient and fast. Stack with Selank for anxiety-free cognitive boost.\", \"primary_effects\": [\"executive function\", \"working memory\", \"motivation\", \"ADHD symptoms\", \"neuroprotection\", \"stroke rehabilitation\"], \"safety\": {\"addiction_potential\": \"low\", \"contraindications\": [\"mental health conditions (BDNF implications)\", \"epilepsy\"], \"drug_interactions\": [\"limited data\"], \"side_effects\": [\"nasal irritation\", \"mild anxiety at high doses\", \"fatigue post-cycle\"], \"tolerance\": \"mild with extended use\", \"toxicity\": \"very low\"}, \"synergistic_stacks\": [{\"compound\": \"Selank\", \"effect\": \"anxiety + cognitive combo — 'Russian stack'\"}, {\"compound\": \"Cerebrolysin\", \"effect\": \"advanced neuroregeneration stack\"}, {\"compound\": \"Noopept\", \"effect\": \"cognitive enhancement stack\"}]}"}
{"record_id": "NTR-008", "dataset": "nootropics", "entry_type": "compound", "name": "Noopept (Omberacetam)", "category": "racetam-like peptide", "goal": null, "mechanisms": ["NGF and BDNF expression upregulation", "AMPA receptor sensitization", "Acetylcholine potentiation", "Alpha wave enhancement", "Neuroprotection vs glutamate excitotoxicity"], "primary_effects": ["memory", "learning", "neuroprotection", "mood", "focus"], "dosing_summary": "{\"administration\": [\"oral\", \"sublingual (faster)\", \"intranasal\"], \"frequency\": \"2-3x per day\", \"half_life_minutes\": 30, \"high\": \"30-60mg/day\", \"onset_minutes\": 15, \"standard\": \"10-30mg/day\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"severe hepatic/renal impairment\"], \"side_effects\": [\"irritability\", \"brain fog (paradoxical)\", \"headache\", \"insomnia\"], \"tolerance\": \"low\", \"toxicity\": \"very low — 1000x more potent than piracetam by weight\"}", "evidence_level": "moderate (primarily Russian/Eastern European)", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"157115-85-0\", \"category\": \"racetam-like peptide\", \"clinical_evidence\": {\"level\": \"moderate (primarily Russian/Eastern European)\", \"pubmed_ids\": [\"10977920\"], \"studies\": [\"cognitive impairment\", \"Alzheimer's adjunct\", \"anxiety-cognitive combo\"]}, \"cost_per_month_usd\": 10, \"dosing\": {\"administration\": [\"oral\", \"sublingual (faster)\", \"intranasal\"], \"frequency\": \"2-3x per day\", \"half_life_minutes\": 30, \"high\": \"30-60mg/day\", \"onset_minutes\": 15, \"standard\": \"10-30mg/day\"}, \"id\": \"NTR-008\", \"legal_status\": {\"EU\": \"unregulated\", \"RU\": \"approved drug\", \"US\": \"unscheduled\"}, \"mechanisms\": [\"NGF and BDNF expression upregulation\", \"AMPA receptor sensitization\", \"Acetylcholine potentiation\", \"Alpha wave enhancement\", \"Neuroprotection vs glutamate excitotoxicity\"], \"molecular_formula\": \"C17H22N2O4\", \"name\": \"Noopept (Omberacetam)\", \"notes\": \"Extremely potent per mg. Start low (10mg). Good value. Cycles recommended to prevent tolerance.\", \"primary_effects\": [\"memory\", \"learning\", \"neuroprotection\", \"mood\", \"focus\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"severe hepatic/renal impairment\"], \"side_effects\": [\"irritability\", \"brain fog (paradoxical)\", \"headache\", \"insomnia\"], \"tolerance\": \"low\", \"toxicity\": \"very low — 1000x more potent than piracetam by weight\"}}"}
{"record_id": "NTR-009", "dataset": "nootropics", "entry_type": "compound", "name": "Ashwagandha (KSM-66)", "category": "adaptogen", "goal": null, "mechanisms": ["HPA axis normalization", "Cortisol reduction (11β-HSD1 inhibition)", "GABA-A receptor modulation", "Testosterone upregulation (LH potentiation)", "Thyroid support (T3/T4 normalization)", "Anti-inflammatory (NF-kB inhibition)"], "primary_effects": ["stress reduction", "anxiety", "testosterone", "strength/recovery", "thyroid function", "sleep quality"], "dosing_summary": "{\"administration\": [\"oral\"], \"frequency\": \"1-2x per day\", \"high\": \"600-1200mg/day\", \"peak_effect_weeks\": 8, \"standard\": \"300-600mg/day (KSM-66 or Sensoril)\"}", "safety_summary": "{\"addiction_potential\": \"none\", \"contraindications\": [\"hyperthyroidism\", \"autoimmune (theoretical)\", \"pregnancy\"], \"drug_interactions\": [\"thyroid medications\", \"immunosuppressants\", \"sedatives\"], \"side_effects\": [\"GI upset\", \"drowsiness\", \"thyroid overstimulation\"], \"toxicity\": \"very low\"}", "evidence_level": "strong", "source_file": "nootropics/nootropics_database.json", "raw": "{\"active_compounds\": [\"withanolides\", \"sitoindosides\", \"alkaloids\"], \"cas_number\": \"N/A\", \"category\": \"adaptogen\", \"clinical_evidence\": {\"level\": \"strong\", \"pubmed_ids\": [\"23439798\", \"25405876\", \"32242751\"], \"studies\": [\"cortisol reduction RCT\", \"testosterone increase\", \"strength performance\", \"anxiety\", \"thyroid function\"]}, \"cost_per_month_usd\": 20, \"dosing\": {\"administration\": [\"oral\"], \"frequency\": \"1-2x per day\", \"high\": \"600-1200mg/day\", \"peak_effect_weeks\": 8, \"standard\": \"300-600mg/day (KSM-66 or Sensoril)\"}, \"id\": \"NTR-009\", \"legal_status\": {\"EU\": \"food supplement\", \"IN\": \"traditional medicine\", \"US\": \"dietary supplement\"}, \"mechanisms\": [\"HPA axis normalization\", \"Cortisol reduction (11β-HSD1 inhibition)\", \"GABA-A receptor modulation\", \"Testosterone upregulation (LH potentiation)\", \"Thyroid support (T3/T4 normalization)\", \"Anti-inflammatory (NF-kB inhibition)\"], \"name\": \"Ashwagandha (KSM-66)\", \"notes\": \"Best studied adaptogen. KSM-66 > Sensoril for testosterone; Sensoril better for anxiety. Quality varies — check withanolide %. One of most evidence-backed supplements overall.\", \"primary_effects\": [\"stress reduction\", \"anxiety\", \"testosterone\", \"strength/recovery\", \"thyroid function\", \"sleep quality\"], \"safety\": {\"addiction_potential\": \"none\", \"contraindications\": [\"hyperthyroidism\", \"autoimmune (theoretical)\", \"pregnancy\"], \"drug_interactions\": [\"thyroid medications\", \"immunosuppressants\", \"sedatives\"], \"side_effects\": [\"GI upset\", \"drowsiness\", \"thyroid overstimulation\"], \"toxicity\": \"very low\"}, \"synergistic_stacks\": [{\"compound\": \"Bacopa\", \"effect\": \"stress + memory\"}, {\"compound\": \"Rhodiola\", \"effect\": \"energy + stress resilience\"}, {\"compound\": \"Fadogia Agrestis\", \"effect\": \"testosterone optimization stack\"}]}"}
{"record_id": "NTR-010", "dataset": "nootropics", "entry_type": "compound", "name": "Phenylpiracetam", "category": "racetam", "goal": null, "mechanisms": ["Dopamine receptor density upregulation", "Norepinephrine potentiation", "Acetylcholine enhancement", "Alpha-adrenergic agonism", "Psychomotor stimulation"], "primary_effects": ["stimulation", "focus", "physical performance", "cold resistance", "cognitive speed"], "dosing_summary": "{\"administration\": [\"oral\"], \"frequency\": \"max 2-3x per WEEK (rapid tolerance)\", \"half_life_hours\": 5, \"onset_minutes\": 30, \"standard\": \"100-200mg/dose\"}", "safety_summary": "{\"addiction_potential\": \"low\", \"contraindications\": [\"cardiovascular issues\", \"hypertension\", \"anxiety disorders\"], \"side_effects\": [\"insomnia\", \"irritability\", \"anxiety\", \"rapid tolerance\"], \"tolerance\": \"RAPID — use sparingly, max 2-3x/week\", \"toxicity\": \"low\"}", "evidence_level": "moderate (Eastern European)", "source_file": "nootropics/nootropics_database.json", "raw": "{\"cas_number\": \"77472-70-9\", \"category\": \"racetam\", \"clinical_evidence\": {\"level\": \"moderate (Eastern European)\", \"studies\": [\"epilepsy adjunct\", \"stroke recovery\", \"cognitive impairment\"]}, \"cost_per_month_usd\": 25, \"dosing\": {\"administration\": [\"oral\"], \"frequency\": \"max 2-3x per WEEK (rapid tolerance)\", \"half_life_hours\": 5, \"onset_minutes\": 30, \"standard\": \"100-200mg/dose\"}, \"id\": \"NTR-010\", \"legal_status\": {\"RU\": \"prescription\", \"US\": \"unscheduled\", \"WADA\": \"BANNED in sports\"}, \"mechanisms\": [\"Dopamine receptor density upregulation\", \"Norepinephrine potentiation\", \"Acetylcholine enhancement\", \"Alpha-adrenergic agonism\", \"Psychomotor stimulation\"], \"molecular_formula\": \"C12H14N2O2\", \"name\": \"Phenylpiracetam\", \"notes\": \"The stimulant racetam. Banned by WADA. Reserve for demanding days — tolerance develops within 3 consecutive days. More stimulating than modafinil.\", \"primary_effects\": [\"stimulation\", \"focus\", \"physical performance\", \"cold resistance\", \"cognitive speed\"], \"safety\": {\"addiction_potential\": \"low\", \"contraindications\": [\"cardiovascular issues\", \"hypertension\", \"anxiety disorders\"], \"side_effects\": [\"insomnia\", \"irritability\", \"anxiety\", \"rapid tolerance\"], \"tolerance\": \"RAPID — use sparingly, max 2-3x/week\", \"toxicity\": \"low\"}}"}
{"record_id": "PEP-001", "dataset": "peptides", "entry_type": "compound", "name": "BPC-157", "category": null, "goal": null, "mechanisms": ["VEGF upregulation — promotes angiogenesis", "eNOS pathway activation", "Tendon fibroblast proliferation", "FAK-paxillin pathway activation", "Nitric oxide system modulation", "Growth hormone receptor upregulation", "Gut mucosal healing", "Anti-inflammatory (NF-κB inhibition)"], "primary_effects": ["Tendon and ligament healing", "Gut healing (IBD, leaky gut, ulcers)", "Muscle healing post-injury", "Joint repair", "Neuroprotection", "Systemic anti-inflammation"], "dosing_summary": "{\"administration\": {\"intramuscular\": {\"notes\": \"Faster local effect\", \"preferred_for\": \"localized muscle injury\"}, \"intranasal\": {\"notes\": \"Emerging use\", \"preferred_for\": \"neuroprotection, brain effects\"}, \"oral\": {\"notes\": \"Poor systemic bioavailability but locally active in GI tract\", \"preferred_for\": \"gut healing only\"}, \"subcutaneous\": {\"injection_site\": \"near injury site or belly fat\", \"notes\": \"Most studied route\", \"preferred_for\": \"systemic effects\"}}, \"break_weeks\": 2, \"cycle_weeks\": 4, \"frequency\": \"once or twice daily\", \"high_mcg\": 500, \"standard_mcg\": 250}", "safety_summary": "{\"cancer_concern\": \"theoretical due to angiogenesis promotion — not demonstrated in practice\", \"contraindications\": [\"active cancer (VEGF concern theoretical)\", \"pregnancy\"], \"drug_interactions\": [\"NSAIDs may reduce efficacy (competing pathways)\", \"anticoagulants\"], \"human_data\": \"limited formal trials — primarily rodent data + anecdotal human use\", \"side_effects\": [\"injection site discomfort\", \"nausea (oral)\", \"dizziness (rare)\", \"growth stimulation concern (theoretical)\"], \"toxicity\": \"very low — no LD50 established in rodents even at extreme doses\"}", "evidence_level": null, "source_file": "peptides/peptides_database.json", "raw": "{\"amino_acids\": 15, \"cas_number\": \"137525-51-0\", \"dosing\": {\"administration\": {\"intramuscular\": {\"notes\": \"Faster local effect\", \"preferred_for\": \"localized muscle injury\"}, \"intranasal\": {\"notes\": \"Emerging use\", \"preferred_for\": \"neuroprotection, brain effects\"}, \"oral\": {\"notes\": \"Poor systemic bioavailability but locally active in GI tract\", \"preferred_for\": \"gut healing only\"}, \"subcutaneous\": {\"injection_site\": \"near injury site or belly fat\", \"notes\": \"Most studied route\", \"preferred_for\": \"systemic effects\"}}, \"break_weeks\": 2, \"cycle_weeks\": 4, \"frequency\": \"once or twice daily\", \"high_mcg\": 500, \"standard_mcg\": 250}, \"evidence\": {\"animal_studies\": \"extensive — hundreds of studies in rodents\", \"human_studies\": \"limited formal trials, extensive community reports\", \"pubmed_ids\": [\"8851498\", \"10415124\", \"21091418\", \"23372999\"]}, \"full_name\": \"Body Protection Compound-157\", \"id\": \"PEP-001\", \"mechanisms\": [\"VEGF upregulation — promotes angiogenesis\", \"eNOS pathway activation\", \"Tendon fibroblast proliferation\", \"FAK-paxillin pathway activation\", \"Nitric oxide system modulation\", \"Growth hormone receptor upregulation\", \"Gut mucosal healing\", \"Anti-inflammatory (NF-κB inhibition)\"], \"molecular_weight\": 1419.55, \"name\": \"BPC-157\", \"notes\": \"One of the most popular research peptides. Exceptional safety profile in animal data. 'The wolverine peptide'. Gut healing at oral doses is well evidenced. Systemic repair requires injection.\", \"origin\": \"gastric juice peptide fraction\", \"primary_effects\": [\"Tendon and ligament healing\", \"Gut healing (IBD, leaky gut, ulcers)\", \"Muscle healing post-injury\", \"Joint repair\", \"Neuroprotection\", \"Systemic anti-inflammation\"], \"reconstitution\": {\"solvent\": \"bacteriostatic water or sterile saline\", \"storage_lyophilized\": \"freezer or room temp, away from light\", \"storage_reconstituted\": \"refrigerate 2-8°C, use within 30 days\", \"typical_vial_mg\": 5}, \"safety\": {\"cancer_concern\": \"theoretical due to angiogenesis promotion — not demonstrated in practice\", \"contraindications\": [\"active cancer (VEGF concern theoretical)\", \"pregnancy\"], \"drug_interactions\": [\"NSAIDs may reduce efficacy (competing pathways)\", \"anticoagulants\"], \"human_data\": \"limited formal trials — primarily rodent data + anecdotal human use\", \"side_effects\": [\"injection site discomfort\", \"nausea (oral)\", \"dizziness (rare)\", \"growth stimulation concern (theoretical)\"], \"toxicity\": \"very low — no LD50 established in rodents even at extreme doses\"}, \"sequence\": \"GEPPPGKPADDAGLV\", \"synergistic_stacks\": [{\"compound\": \"TB-500\", \"effect\": \"comprehensive injury healing — the gold standard combo\", \"ratio\": \"BPC-157 250-500mcg + TB-500 2-5mg, 2x/week\"}, {\"compound\": \"Ipamorelin\", \"effect\": \"GH + healing stack\"}, {\"compound\": \"Hexarelin\", \"effect\": \"cardioprotection + healing\"}]}"}
{"record_id": "PEP-002", "dataset": "peptides", "entry_type": "compound", "name": "TB-500", "category": null, "goal": null, "mechanisms": ["Actin sequestering — promotes cell migration", "Stem cell differentiation support", "Anti-inflammatory (down-regulates inflammatory cytokines)", "Angiogenesis via Krüppel-like factor 2", "Cardiac muscle protection", "Blood vessel formation", "Hair follicle stimulation"], "primary_effects": ["Systemic tissue repair", "Chronic injury healing", "Cardiovascular protection", "Anti-fibrotic", "Flexibility improvement", "Wound healing", "Hair regrowth"], "dosing_summary": "{\"administration\": [\"subcutaneous\", \"intramuscular\"], \"loading_phase\": {\"dose_mg\": 5, \"duration_weeks\": 4, \"frequency\": \"twice weekly\", \"note\": \"Loading phase builds tissue levels\"}, \"maintenance_phase\": {\"dose_mg\": 2.5, \"duration_weeks\": \"ongoing\", \"frequency\": \"twice weekly\"}}", "safety_summary": "{\"contraindications\": [\"active cancer\", \"pregnancy\"], \"human_data\": \"Phase I/II trials (cardiac repair) — generally well tolerated\", \"side_effects\": [\"injection site pain\", \"head rush (brief)\", \"fatigue\", \"nausea (rare)\"], \"toxicity\": \"low\"}", "evidence_level": null, "source_file": "peptides/peptides_database.json", "raw": "{\"cas_number\": \"77591-33-4\", \"dosing\": {\"administration\": [\"subcutaneous\", \"intramuscular\"], \"loading_phase\": {\"dose_mg\": 5, \"duration_weeks\": 4, \"frequency\": \"twice weekly\", \"note\": \"Loading phase builds tissue levels\"}, \"maintenance_phase\": {\"dose_mg\": 2.5, \"duration_weeks\": \"ongoing\", \"frequency\": \"twice weekly\"}}, \"evidence\": {\"animal_studies\": \"strong — cardiac, CNS, wound healing\", \"human_studies\": \"cardiac trial data + anecdotal\", \"pubmed_ids\": [\"15175747\", \"17067254\", \"26178161\"]}, \"full_name\": \"Thymosin Beta-4 fragment (17-23)\", \"id\": \"PEP-002\", \"mechanisms\": [\"Actin sequestering — promotes cell migration\", \"Stem cell differentiation support\", \"Anti-inflammatory (down-regulates inflammatory cytokines)\", \"Angiogenesis via Krüppel-like factor 2\", \"Cardiac muscle protection\", \"Blood vessel formation\", \"Hair follicle stimulation\"], \"molecular_weight\": 888.0, \"name\": \"TB-500\", \"notes\": \"Works systemically, not just locally. Excellent for chronic/old injuries that have stopped healing. The BPC-157 + TB-500 combo is considered the biohacking standard for repair.\", \"origin\": \"synthetic fragment of endogenous Thymosin Beta-4\", \"primary_effects\": [\"Systemic tissue repair\", \"Chronic injury healing\", \"Cardiovascular protection\", \"Anti-fibrotic\", \"Flexibility improvement\", \"Wound healing\", \"Hair regrowth\"], \"reconstitution\": {\"solvent\": \"bacteriostatic water\", \"storage_reconstituted\": \"refrigerate 2-8°C, use within 30 days\", \"typical_vial_mg\": 5}, \"safety\": {\"contraindications\": [\"active cancer\", \"pregnancy\"], \"human_data\": \"Phase I/II trials (cardiac repair) — generally well tolerated\", \"side_effects\": [\"injection site pain\", \"head rush (brief)\", \"fatigue\", \"nausea (rare)\"], \"toxicity\": \"low\"}, \"sequence\": \"LKKTETQ\", \"synergistic_stacks\": [{\"compound\": \"BPC-157\", \"effect\": \"The classic combo — complementary mechanisms, comprehensive healing\"}, {\"compound\": \"GHK-Cu\", \"effect\": \"tissue regeneration + anti-aging\"}, {\"compound\": \"IGF-1 LR3\", \"effect\": \"muscle + systemic tissue repair\"}]}"}
{"record_id": "PEP-003", "dataset": "peptides", "entry_type": "compound", "name": "Ipamorelin", "category": "GHRP (Growth Hormone Releasing Peptide)", "goal": null, "mechanisms": ["Selective GHS-R1a agonist", "Pulsatile GH release from pituitary", "Ghrelin receptor activation", "No cortisol or prolactin increase (unlike other GHRPs)"], "primary_effects": ["GH pulse stimulation", "fat loss", "muscle preservation", "sleep quality", "recovery"], "dosing_summary": "{\"administration\": [\"subcutaneous\", \"intramuscular\"], \"cycle\": \"12 weeks on, 4 weeks off\", \"frequency\": \"2-3x per day\", \"optimal_timing\": [\"fasted — AM\", \"pre-workout\", \"before bed (strongest GH pulse during sleep)\"], \"range_mcg\": \"100-300\", \"standard_mcg\": 200}", "safety_summary": "{\"contraindications\": [\"active cancer\", \"pregnancy\", \"acromegaly\"], \"drug_interactions\": [\"insulin — timing\", \"glucocorticoids reduce effect\"], \"side_effects\": [\"water retention\", \"mild hunger\", \"tingling/numbness (carpal tunnel at high GH)\", \"cortisol (minimal)\"], \"toxicity\": \"low\"}", "evidence_level": null, "source_file": "peptides/peptides_database.json", "raw": "{\"cas_number\": \"170851-70-4\", \"category\": \"GHRP (Growth Hormone Releasing Peptide)\", \"dosing\": {\"administration\": [\"subcutaneous\", \"intramuscular\"], \"cycle\": \"12 weeks on, 4 weeks off\", \"frequency\": \"2-3x per day\", \"optimal_timing\": [\"fasted — AM\", \"pre-workout\", \"before bed (strongest GH pulse during sleep)\"], \"range_mcg\": \"100-300\", \"standard_mcg\": 200}, \"id\": \"PEP-003\", \"mechanisms\": [\"Selective GHS-R1a agonist\", \"Pulsatile GH release from pituitary\", \"Ghrelin receptor activation\", \"No cortisol or prolactin increase (unlike other GHRPs)\"], \"molecular_weight\": 711.85, \"name\": \"Ipamorelin\", \"notes\": \"Cleanest GHRP — no cortisol/prolactin spike unlike hexarelin or GHRP-2. Best option for long-term GH optimization. Stack with CJC-1295 for 3-5x amplification.\", \"primary_effects\": [\"GH pulse stimulation\", \"fat loss\", \"muscle preservation\", \"sleep quality\", \"recovery\"], \"safety\": {\"contraindications\": [\"active cancer\", \"pregnancy\", \"acromegaly\"], \"drug_interactions\": [\"insulin — timing\", \"glucocorticoids reduce effect\"], \"side_effects\": [\"water retention\", \"mild hunger\", \"tingling/numbness (carpal tunnel at high GH)\", \"cortisol (minimal)\"], \"toxicity\": \"low\"}, \"synergistic_stacks\": [{\"compound\": \"CJC-1295 (DAC)\", \"effect\": \"The gold standard GH stack — GHRH + GHRP synergy, 3-5x GH pulse\"}, {\"compound\": \"GHRP-6\", \"effect\": \"stronger GH pulse, more hunger\"}, {\"compound\": \"BPC-157\", \"effect\": \"healing + GH optimization\"}]}"}
{"record_id": "PEP-004", "dataset": "peptides", "entry_type": "compound", "name": "CJC-1295 (with DAC)", "category": "GHRH analogue", "goal": null, "mechanisms": ["GHRH receptor agonism", "Sustained GH secretion via DAC (half-life extension)", "IGF-1 upregulation", "Pituitary sensitization to GHRP"], "primary_effects": ["sustained GH elevation", "IGF-1 increase", "muscle growth", "fat loss", "recovery", "anti-aging"], "dosing_summary": "{\"administration\": [\"subcutaneous\"], \"frequency\": \"1-2x per week (due to long half-life from DAC)\", \"half_life_days\": 6, \"note\": \"CJC-1295 without DAC = Mod GRF 1-29 — very different dosing (2-3x/day)\", \"standard_mcg\": 1000}", "safety_summary": "{\"contraindications\": [\"active cancer\", \"diabetes\", \"acromegaly\", \"pregnancy\"], \"side_effects\": [\"water retention\", \"joint pain (GH related)\", \"fatigue\", \"hypoglycemia (rare)\"]}", "evidence_level": null, "source_file": "peptides/peptides_database.json", "raw": "{\"category\": \"GHRH analogue\", \"dosing\": {\"administration\": [\"subcutaneous\"], \"frequency\": \"1-2x per week (due to long half-life from DAC)\", \"half_life_days\": 6, \"note\": \"CJC-1295 without DAC = Mod GRF 1-29 — very different dosing (2-3x/day)\", \"standard_mcg\": 1000}, \"full_name\": \"Drug Affinity Complex Growth Hormone Releasing Factor\", \"id\": \"PEP-004\", \"mechanisms\": [\"GHRH receptor agonism\", \"Sustained GH secretion via DAC (half-life extension)\", \"IGF-1 upregulation\", \"Pituitary sensitization to GHRP\"], \"molecular_weight\": 3647.28, \"name\": \"CJC-1295 (with DAC)\", \"notes\": \"The 'set and forget' GH peptide — once or twice weekly dosing. Always stack with a GHRP for synergistic effect.\", \"primary_effects\": [\"sustained GH elevation\", \"IGF-1 increase\", \"muscle growth\", \"fat loss\", \"recovery\", \"anti-aging\"], \"safety\": {\"contraindications\": [\"active cancer\", \"diabetes\", \"acromegaly\", \"pregnancy\"], \"side_effects\": [\"water retention\", \"joint pain (GH related)\", \"fatigue\", \"hypoglycemia (rare)\"]}, \"synergistic_stacks\": [{\"compound\": \"Ipamorelin\", \"effect\": \"Best GH stack — amplified pulsatile release\"}, {\"compound\": \"GHRP-2\", \"effect\": \"more aggressive GH release\"}]}"}
{"record_id": "PEP-005", "dataset": "peptides", "entry_type": "compound", "name": "Selank", "category": "anxiolytic peptide", "goal": null, "mechanisms": ["Enkephalinase inhibition (endorphin preservation)", "BDNF upregulation", "IL-6 modulation", "GABAergic modulation (non-benzodiazepine)", "Dopamine, serotonin, norepinephrine balance"], "primary_effects": ["anxiety elimination", "cognitive clarity", "stress resilience", "mood stabilization", "memory"], "dosing_summary": "{\"administration\": [\"intranasal (preferred)\", \"subcutaneous\"], \"cycle\": \"2-4 weeks continuous, then break\", \"frequency\": \"1-2x per day\", \"range_mcg\": \"250-1000\", \"standard_mcg\": 250}", "safety_summary": "{\"addiction_potential\": \"none — unlike benzodiazepines\", \"contraindications\": [], \"side_effects\": [\"mild sedation\", \"nasal irritation (intranasal)\"], \"toxicity\": \"very low\"}", "evidence_level": null, "source_file": "peptides/peptides_database.json", "raw": "{\"cas_number\": \"129954-34-3\", \"category\": \"anxiolytic peptide\", \"dosing\": {\"administration\": [\"intranasal (preferred)\", \"subcutaneous\"], \"cycle\": \"2-4 weeks continuous, then break\", \"frequency\": \"1-2x per day\", \"range_mcg\": \"250-1000\", \"standard_mcg\": 250}, \"id\": \"PEP-005\", \"mechanisms\": [\"Enkephalinase inhibition (endorphin preservation)\", \"BDNF upregulation\", \"IL-6 modulation\", \"GABAergic modulation (non-benzodiazepine)\", \"Dopamine, serotonin, norepinephrine balance\"], \"molecular_weight\": 751.9, \"name\": \"Selank\", \"notes\": \"Non-addictive anxiolytic with cognitive-enhancing properties. Approved in Russia. Used as benzodiazepine alternative.\", \"primary_effects\": [\"anxiety elimination\", \"cognitive clarity\", \"stress resilience\", \"mood stabilization\", \"memory\"], \"safety\": {\"addiction_potential\": \"none — unlike benzodiazepines\", \"contraindications\": [], \"side_effects\": [\"mild sedation\", \"nasal irritation (intranasal)\"], \"toxicity\": \"very low\"}, \"sequence\": \"TKPRPGP\", \"synergistic_stacks\": [{\"compound\": \"Semax\", \"effect\": \"The 'Russian stack' — anxiety-free cognitive enhancement\"}, {\"compound\": \"Noopept\", \"effect\": \"cognition without anxiety\"}]}"}
{"record_id": "PEP-006", "dataset": "peptides", "entry_type": "compound", "name": "GHK-Cu (Copper Peptide)", "category": null, "goal": null, "mechanisms": ["Copper delivery to tissues", "Collagen and elastin synthesis", "Superoxide dismutase activation", "Anti-inflammatory gene activation (>4000 genes modulated)", "Stem cell activation", "DNA repair enhancement", "Anti-fibrotic"], "primary_effects": ["skin repair and anti-aging", "wound healing", "hair regrowth", "anti-inflammation", "systemic repair"], "dosing_summary": "{\"subcutaneous\": {\"dose_mg\": \"0.5-2\", \"frequency\": \"daily to 3x/week\", \"notes\": \"Systemic anti-aging use\"}, \"topical\": {\"application\": \"affected area\", \"concentration_percent\": \"0.1-1\", \"frequency\": \"1-2x per day\"}}", "safety_summary": "{\"notes\": \"One of the safest peptides — naturally occurring, declining with age\", \"side_effects\": [\"copper excess at very high doses (theoretical)\"], \"toxicity\": \"very low — endogenous compound\"}", "evidence_level": "strong for topical, moderate for systemic", "source_file": "peptides/peptides_database.json", "raw": "{\"cas_number\": \"49557-75-7\", \"dosing\": {\"subcutaneous\": {\"dose_mg\": \"0.5-2\", \"frequency\": \"daily to 3x/week\", \"notes\": \"Systemic anti-aging use\"}, \"topical\": {\"application\": \"affected area\", \"concentration_percent\": \"0.1-1\", \"frequency\": \"1-2x per day\"}}, \"evidence\": {\"level\": \"strong for topical, moderate for systemic\", \"pubmed_ids\": [\"24553997\", \"25741251\", \"30970185\"]}, \"full_name\": \"Glycyl-L-histidyl-L-lysine copper complex\", \"id\": \"PEP-006\", \"mechanisms\": [\"Copper delivery to tissues\", \"Collagen and elastin synthesis\", \"Superoxide dismutase activation\", \"Anti-inflammatory gene activation (>4000 genes modulated)\", \"Stem cell activation\", \"DNA repair enhancement\", \"Anti-fibrotic\"], \"molecular_weight\": 340.38, \"name\": \"GHK-Cu (Copper Peptide)\", \"notes\": \"Naturally produced by the body, declines with age. Endocrine disruptor in skin aging. Strong anti-aging profile — modulates thousands of genes.\", \"primary_effects\": [\"skin repair and anti-aging\", \"wound healing\", \"hair regrowth\", \"anti-inflammation\", \"systemic repair\"], \"safety\": {\"notes\": \"One of the safest peptides — naturally occurring, declining with age\", \"side_effects\": [\"copper excess at very high doses (theoretical)\"], \"toxicity\": \"very low — endogenous compound\"}, \"synergistic_stacks\": [{\"compound\": \"TB-500\", \"effect\": \"comprehensive tissue regeneration\"}, {\"compound\": \"BPC-157\", \"effect\": \"synergistic wound healing\"}, {\"compound\": \"NAD+\", \"effect\": \"anti-aging multipronged approach\"}]}"}
{"record_id": "PEP-007", "dataset": "peptides", "entry_type": "compound", "name": "Epithalon (Epitalon)", "category": null, "goal": null, "mechanisms": ["Telomerase activation (hTERT upregulation)", "Pineal gland stimulation → melatonin normalization", "Antioxidant gene activation", "Tumor suppressor gene activation", "Circadian rhythm restoration"], "primary_effects": ["telomere lengthening", "longevity", "sleep normalization", "anti-cancer (reported)", "immune optimization"], "dosing_summary": "{\"course_protocol\": {\"administration\": [\"subcutaneous\", \"intramuscular\", \"intranasal\"], \"dose_mg\": 5, \"duration_days\": 10, \"frequency\": \"once daily\", \"frequency_of_courses\": \"1-2 per year\"}}", "safety_summary": "{\"contraindications\": [\"active cancer (theoretical — telomerase)\"], \"side_effects\": [\"injection site reaction\", \"vivid dreams (melatonin effect)\"], \"toxicity\": \"very low\"}", "evidence_level": "moderate — Khavinson Institute data (Russia)", "source_file": "peptides/peptides_database.json", "raw": "{\"cas_number\": \"307297-39-8\", \"dosing\": {\"course_protocol\": {\"administration\": [\"subcutaneous\", \"intramuscular\", \"intranasal\"], \"dose_mg\": 5, \"duration_days\": 10, \"frequency\": \"once daily\", \"frequency_of_courses\": \"1-2 per year\"}}, \"evidence\": {\"animal_studies\": \"life extension in mice 25%\", \"human_studies\": \"limited formal trials, longitudinal Khavinson studies\", \"level\": \"moderate — Khavinson Institute data (Russia)\", \"pubmed_ids\": [\"12374906\", \"14523363\", \"21058889\"]}, \"full_name\": \"Epithalamin tetrapeptide\", \"id\": \"PEP-007\", \"mechanisms\": [\"Telomerase activation (hTERT upregulation)\", \"Pineal gland stimulation → melatonin normalization\", \"Antioxidant gene activation\", \"Tumor suppressor gene activation\", \"Circadian rhythm restoration\"], \"molecular_weight\": 390.35, \"name\": \"Epithalon (Epitalon)\", \"notes\": \"The longevity peptide. Most researched peptide for life extension. Khavinson's research spans 40+ years. Annual courses common in longevity protocols.\", \"primary_effects\": [\"telomere lengthening\", \"longevity\", \"sleep normalization\", \"anti-cancer (reported)\", \"immune optimization\"], \"safety\": {\"contraindications\": [\"active cancer (theoretical — telomerase)\"], \"side_effects\": [\"injection site reaction\", \"vivid dreams (melatonin effect)\"], \"toxicity\": \"very low\"}, \"sequence\": \"AEDG\"}"}
{"record_id": "LON-001", "dataset": "longevity", "entry_type": "compound", "name": "Rapamycin (Sirolimus)", "category": "mTOR inhibitor", "goal": null, "mechanisms": ["mTORC1 inhibition via FKBP12 complex", "Autophagy induction", "Senescent cell burden reduction", "Immune system rejuvenation", "Translation regulation"], "primary_effects": [], "dosing_summary": "{\"aggressive\": {\"dose_mg\": \"2-5\", \"frequency\": \"daily\", \"note\": \"Classical transplant-derived approach, higher side effect risk\"}, \"alan_green_protocol\": {\"dose_mg\": 6, \"frequency\": \"weekly\", \"note\": \"Popular longevity physician protocol\"}, \"intermittent_biohacking\": {\"dose_mg\": \"5-10\", \"frequency\": \"once weekly\", \"rationale\": \"mTORC2 sparing — reduces metabolic side effects\"}}", "safety_summary": "{\"contraindications\": [\"active infection\", \"immunocompromised baseline\", \"pregnancy\"], \"drug_interactions\": [\"CYP3A4 substrate — grapefruit, many drugs\"], \"monitoring\": [\"lipids\", \"glucose\", \"CBC\", \"infection status\"], \"side_effects_chronic_high_dose\": [\"immunosuppression\", \"insulin resistance\", \"hyperlipidemia\", \"mouth sores\", \"impaired wound healing\"], \"side_effects_intermittent_low_dose\": [\"mouth sores\", \"mild lipid changes\"]}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"53123-88-9\", \"category\": \"mTOR inhibitor\", \"dosing_protocols\": {\"aggressive\": {\"dose_mg\": \"2-5\", \"frequency\": \"daily\", \"note\": \"Classical transplant-derived approach, higher side effect risk\"}, \"alan_green_protocol\": {\"dose_mg\": 6, \"frequency\": \"weekly\", \"note\": \"Popular longevity physician protocol\"}, \"intermittent_biohacking\": {\"dose_mg\": \"5-10\", \"frequency\": \"once weekly\", \"rationale\": \"mTORC2 sparing — reduces metabolic side effects\"}}, \"hallmarks_targeted\": [\"deregulated nutrient sensing\", \"cellular senescence\", \"stem cell exhaustion\", \"loss of proteostasis\"], \"id\": \"LON-001\", \"legal_status\": \"prescription (transplant immunosuppressant)\", \"longevity_evidence\": {\"human_data\": \"Phase I/II trials in elderly immune function (Stanford, TRIIM-X)\", \"itp_study\": \"confirmed across 3 independent labs\", \"mechanistic_consensus\": \"strongest longevity evidence of any compound\", \"mouse_lifespan_extension_percent\": \"9-23% (ITP data)\"}, \"mechanisms\": [\"mTORC1 inhibition via FKBP12 complex\", \"Autophagy induction\", \"Senescent cell burden reduction\", \"Immune system rejuvenation\", \"Translation regulation\"], \"name\": \"Rapamycin (Sirolimus)\", \"safety\": {\"contraindications\": [\"active infection\", \"immunocompromised baseline\", \"pregnancy\"], \"drug_interactions\": [\"CYP3A4 substrate — grapefruit, many drugs\"], \"monitoring\": [\"lipids\", \"glucose\", \"CBC\", \"infection status\"], \"side_effects_chronic_high_dose\": [\"immunosuppression\", \"insulin resistance\", \"hyperlipidemia\", \"mouth sores\", \"impaired wound healing\"], \"side_effects_intermittent_low_dose\": [\"mouth sores\", \"mild lipid changes\"]}, \"synergistic_stack\": [{\"compound\": \"Metformin\", \"effect\": \"AMPK + mTOR — complementary nutrient sensing pathways\"}, {\"compound\": \"Acarbose\", \"effect\": \"ITP confirmed life extension combo\"}, {\"compound\": \"NAD+ precursors\", \"effect\": \"sirtuin + mTOR axis coverage\"}]}"}
{"record_id": "LON-002", "dataset": "longevity", "entry_type": "compound", "name": "Metformin", "category": "AMPK activator / biguanide", "goal": null, "mechanisms": ["Complex I mitochondrial inhibition → AMPK activation", "mTORC1 inhibition (indirect via AMPK)", "FOXO3a activation", "Mitohormesis induction", "microRNA-21 modulation", "Gut microbiome modulation", "Anti-inflammatory (NF-κB inhibition)"], "primary_effects": [], "dosing_summary": "{\"extended_release\": {\"form\": \"Metformin XR\", \"note\": \"Better GI tolerability, same efficacy\"}, \"standard_longevity\": {\"dose_mg\": \"500-1000\", \"frequency\": \"1-2x daily with meals\", \"titration\": \"start 500mg, increase slowly to reduce GI side effects\"}}", "safety_summary": "{\"contraindications\": [\"eGFR <30\", \"hepatic failure\", \"IV contrast (hold 48h)\", \"alcoholism\"], \"exercise_concern\": \"may blunt mitochondrial adaptations from exercise — consider timing\", \"monitoring\": [\"B12 annually\", \"creatinine/eGFR\", \"CBC\"], \"side_effects\": [\"GI upset (nausea, diarrhea) — dose-dependent\", \"B12 deficiency (long-term)\", \"lactic acidosis (rare — contraindicated in renal failure)\", \"blunts exercise adaptations (controversial)\"]}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"657-24-9\", \"category\": \"AMPK activator / biguanide\", \"dosing_protocols\": {\"extended_release\": {\"form\": \"Metformin XR\", \"note\": \"Better GI tolerability, same efficacy\"}, \"standard_longevity\": {\"dose_mg\": \"500-1000\", \"frequency\": \"1-2x daily with meals\", \"titration\": \"start 500mg, increase slowly to reduce GI side effects\"}}, \"hallmarks_targeted\": [\"deregulated nutrient sensing\", \"mitochondrial dysfunction\", \"chronic inflammation\", \"cellular senescence\"], \"id\": \"LON-002\", \"important_consideration\": \"Some longevity researchers (Peter Attia) suggest metformin may blunt exercise benefits and is not recommended for fit, metabolically healthy individuals. Debate ongoing.\", \"legal_status\": \"prescription (diabetes / off-label longevity)\", \"longevity_evidence\": {\"cancer_prevention\": \"epidemiological association with reduced multiple cancers\", \"diabetic_cohort_data\": \"diabetics on metformin outlive matched non-diabetic controls (Bannister 2014)\", \"mouse_data\": \"modest lifespan extension in some studies\", \"tame_trial\": \"Targeting Aging with Metformin — ongoing FDA trial\"}, \"mechanisms\": [\"Complex I mitochondrial inhibition → AMPK activation\", \"mTORC1 inhibition (indirect via AMPK)\", \"FOXO3a activation\", \"Mitohormesis induction\", \"microRNA-21 modulation\", \"Gut microbiome modulation\", \"Anti-inflammatory (NF-κB inhibition)\"], \"name\": \"Metformin\", \"safety\": {\"contraindications\": [\"eGFR <30\", \"hepatic failure\", \"IV contrast (hold 48h)\", \"alcoholism\"], \"exercise_concern\": \"may blunt mitochondrial adaptations from exercise — consider timing\", \"monitoring\": [\"B12 annually\", \"creatinine/eGFR\", \"CBC\"], \"side_effects\": [\"GI upset (nausea, diarrhea) — dose-dependent\", \"B12 deficiency (long-term)\", \"lactic acidosis (rare — contraindicated in renal failure)\", \"blunts exercise adaptations (controversial)\"]}, \"synergistic_stack\": [{\"compound\": \"Rapamycin\", \"effect\": \"complementary pathway coverage\"}, {\"compound\": \"NMN/NR\", \"effect\": \"counter NAD+ depletion from Complex I inhibition\"}, {\"compound\": \"B12 supplementation\", \"effect\": \"prevent deficiency\"}]}"}
{"record_id": "LON-003", "dataset": "longevity", "entry_type": "compound", "name": "NMN (Nicotinamide Mononucleotide)", "category": "NAD+ precursor", "goal": null, "mechanisms": ["Direct NAD+ precursor (bypasses rate-limiting NAMPT)", "Sirtuin (SIRT1-7) activation via NAD+", "PARP activation for DNA repair", "CD38 substrates — immune function", "Mitochondrial biogenesis (PGC-1α)", "Circadian clock regulation"], "primary_effects": [], "dosing_summary": "{\"high_dose\": {\"dose_mg\": \"1000-2000\", \"note\": \"Sinclair protocol range\"}, \"standard\": {\"dose_mg\": 500, \"form\": \"sublingual or enteric-coated preferred\", \"frequency\": \"once daily (morning)\"}}", "safety_summary": "{\"concern\": \"NAD+ feeds cancer cell metabolism (theoretical — not demonstrated as harmful in humans)\", \"monitoring\": \"none required for standard doses\", \"side_effects\": [\"nausea at high doses\", \"flushing (less than niacin)\", \"GI upset\"], \"toxicity\": \"very low\"}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"1094-61-7\", \"category\": \"NAD+ precursor\", \"dosing_protocols\": {\"high_dose\": {\"dose_mg\": \"1000-2000\", \"note\": \"Sinclair protocol range\"}, \"standard\": {\"dose_mg\": 500, \"form\": \"sublingual or enteric-coated preferred\", \"frequency\": \"once daily (morning)\"}}, \"evidence\": {\"animal\": \"strong — multiple lifespan and healthspan studies in mice\", \"human\": \"safety established, efficacy endpoints still emerging\", \"pubmed_ids\": [\"24905167\", \"31690198\", \"32540397\"]}, \"hallmarks_targeted\": [\"mitochondrial dysfunction\", \"genomic instability\", \"deregulated nutrient sensing\", \"stem cell exhaustion\"], \"id\": \"LON-003\", \"mechanisms\": [\"Direct NAD+ precursor (bypasses rate-limiting NAMPT)\", \"Sirtuin (SIRT1-7) activation via NAD+\", \"PARP activation for DNA repair\", \"CD38 substrates — immune function\", \"Mitochondrial biogenesis (PGC-1α)\", \"Circadian clock regulation\"], \"molecular_formula\": \"C11H15N2O8P\", \"nad_pathway\": \"NMN → NMN transporter (Slc12a8) → intracellular → NMN adenylyltransferase → NAD+\", \"name\": \"NMN (Nicotinamide Mononucleotide)\", \"safety\": {\"concern\": \"NAD+ feeds cancer cell metabolism (theoretical — not demonstrated as harmful in humans)\", \"monitoring\": \"none required for standard doses\", \"side_effects\": [\"nausea at high doses\", \"flushing (less than niacin)\", \"GI upset\"], \"toxicity\": \"very low\"}, \"synergistic_stack\": [{\"compound\": \"Resveratrol\", \"effect\": \"Sinclair protocol — SIRT1 activation + NAD+ substrate\"}, {\"compound\": \"Quercetin\", \"effect\": \"senolytic + NAD+ synergy\"}, {\"compound\": \"Rapamycin\", \"effect\": \"comprehensive aging pathway coverage\"}, {\"compound\": \"TMG (Trimethylglycine)\", \"effect\": \"methyl donor — prevents methylation depletion from NMN\"}], \"vs_NR\": {\"NMN\": \"one step closer to NAD+\", \"NR\": \"Nicotinamide Riboside — must convert to NMN first\", \"debate\": \"ongoing — absorption and tissue distribution differs\", \"human_trial_NMN\": \"Imai 2020 (WUMS) — safe, raises NAD+ in blood\"}}"}
{"record_id": "LON-004", "dataset": "longevity", "entry_type": "compound", "name": "Fisetin", "category": "senolytic flavonoid", "goal": null, "mechanisms": ["Senescent cell elimination (apoptosis induction)", "BCL-2/BCL-XL inhibition in senescent cells", "PI3K/Akt pathway inhibition", "mTOR inhibition", "Anti-inflammatory (NF-κB, AP-1 inhibition)", "Nrf2 activation — antioxidant response", "Sirtuin activation"], "primary_effects": [], "dosing_summary": "{\"daily_maintenance\": {\"dose_mg\": \"100-500\", \"frequency\": \"daily with fat\"}, \"senolytic_pulse\": {\"dose_mg\": \"1000-1500\", \"note\": \"Mayo Clinic inspired protocol\", \"protocol\": \"2 consecutive days per month\", \"rationale\": \"senolytic effect — intermittent high dose clears senescent cells\"}}", "safety_summary": "{\"bioavailability_note\": \"poor oral bioavailability — take with fat, consider liposomal form\", \"side_effects\": [\"GI upset at high doses\"], \"toxicity\": \"very low\"}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"528-48-3\", \"category\": \"senolytic flavonoid\", \"dosing_protocols\": {\"daily_maintenance\": {\"dose_mg\": \"100-500\", \"frequency\": \"daily with fat\"}, \"senolytic_pulse\": {\"dose_mg\": \"1000-1500\", \"note\": \"Mayo Clinic inspired protocol\", \"protocol\": \"2 consecutive days per month\", \"rationale\": \"senolytic effect — intermittent high dose clears senescent cells\"}}, \"found_in\": [\"strawberries (highest)\", \"apples\", \"persimmons\", \"onions\", \"cucumbers\"], \"hallmarks_targeted\": [\"cellular senescence\", \"chronic inflammation\", \"genomic instability\"], \"id\": \"LON-004\", \"longevity_evidence\": {\"mayo_clinic_mouse_study\": \"late-life treatment extended median lifespan 10%, improved healthspan markers\", \"pubmed_ids\": [\"29874514\", \"17726416\"]}, \"mechanisms\": [\"Senescent cell elimination (apoptosis induction)\", \"BCL-2/BCL-XL inhibition in senescent cells\", \"PI3K/Akt pathway inhibition\", \"mTOR inhibition\", \"Anti-inflammatory (NF-κB, AP-1 inhibition)\", \"Nrf2 activation — antioxidant response\", \"Sirtuin activation\"], \"name\": \"Fisetin\", \"safety\": {\"bioavailability_note\": \"poor oral bioavailability — take with fat, consider liposomal form\", \"side_effects\": [\"GI upset at high doses\"], \"toxicity\": \"very low\"}, \"synergistic_stack\": [{\"compound\": \"Quercetin + Dasatinib\", \"effect\": \"the original senolytic combo (D+Q)\"}, {\"compound\": \"Navitoclax\", \"effect\": \"stronger senolytic (research only)\"}, {\"compound\": \"NMN\", \"effect\": \"anti-aging comprehensive stack\"}]}"}
{"record_id": "LON-005", "dataset": "longevity", "entry_type": "compound", "name": "Quercetin", "category": "senolytic / anti-inflammatory flavonoid", "goal": null, "mechanisms": ["Senolytic (BCL-2 family inhibition — weaker than dasatinib)", "PI3K inhibition", "Zinc ionophore (with zinc — antiviral)", "Anti-inflammatory (histamine, NF-κB)", "AMPK activation", "Autophagy promotion"], "primary_effects": [], "dosing_summary": "{\"daily_supplement\": {\"dose_mg\": \"500-1000\", \"form\": \"quercetin phytosome (better bioavailability)\"}, \"senolytic_combo\": {\"compound_combo\": \"Quercetin 1000mg + Dasatinib 100mg (prescription)\", \"evidence\": \"Mayo Clinic human trial in IPF\", \"protocol\": \"2 consecutive days, quarterly\"}}", "safety_summary": "{\"drug_interactions\": [\"CYP3A4 inhibitor\", \"quinolone antibiotics (spacing required)\", \"blood thinners\"], \"side_effects\": [\"GI upset\", \"headache at high doses\"]}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"117-39-5\", \"category\": \"senolytic / anti-inflammatory flavonoid\", \"dosing_protocols\": {\"daily_supplement\": {\"dose_mg\": \"500-1000\", \"form\": \"quercetin phytosome (better bioavailability)\"}, \"senolytic_combo\": {\"compound_combo\": \"Quercetin 1000mg + Dasatinib 100mg (prescription)\", \"evidence\": \"Mayo Clinic human trial in IPF\", \"protocol\": \"2 consecutive days, quarterly\"}}, \"id\": \"LON-005\", \"mechanisms\": [\"Senolytic (BCL-2 family inhibition — weaker than dasatinib)\", \"PI3K inhibition\", \"Zinc ionophore (with zinc — antiviral)\", \"Anti-inflammatory (histamine, NF-κB)\", \"AMPK activation\", \"Autophagy promotion\"], \"name\": \"Quercetin\", \"safety\": {\"drug_interactions\": [\"CYP3A4 inhibitor\", \"quinolone antibiotics (spacing required)\", \"blood thinners\"], \"side_effects\": [\"GI upset\", \"headache at high doses\"]}}"}
{"record_id": "LON-006", "dataset": "longevity", "entry_type": "compound", "name": "Spermidine", "category": "autophagy inducer / polyamine", "goal": null, "mechanisms": ["Autophagy induction (TFEB activation)", "Epigenetic — histone deacetylation inhibition", "Anti-inflammatory", "Mitochondrial membrane potential restoration", "Cardioprotective"], "primary_effects": [], "dosing_summary": "{\"note\": \"wheat germ is most concentrated natural source\", \"standard_mg\": \"1-5 from wheat germ extract\"}", "safety_summary": "{\"side_effects\": [\"GI effects at high doses\"], \"toxicity\": \"very low — endogenous compound declining with age\"}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"124-20-9\", \"category\": \"autophagy inducer / polyamine\", \"dosing\": {\"note\": \"wheat germ is most concentrated natural source\", \"standard_mg\": \"1-5 from wheat germ extract\"}, \"found_in\": [\"wheat germ (highest)\", \"soybeans\", \"mushrooms\", \"peas\", \"blue cheese\"], \"id\": \"LON-006\", \"longevity_evidence\": {\"animal_studies\": \"yeast, worms, flies, mice — consistent lifespan extension\", \"epidemiological\": \"Mediterranean diet spermidine intake correlates with longevity\", \"human_trial\": \"autophagy markers, cardiovascular benefit, cognitive aging\", \"pubmed_ids\": [\"26766514\", \"31882775\", \"28826536\"]}, \"mechanisms\": [\"Autophagy induction (TFEB activation)\", \"Epigenetic — histone deacetylation inhibition\", \"Anti-inflammatory\", \"Mitochondrial membrane potential restoration\", \"Cardioprotective\"], \"name\": \"Spermidine\", \"safety\": {\"side_effects\": [\"GI effects at high doses\"], \"toxicity\": \"very low — endogenous compound declining with age\"}}"}
{"record_id": "LON-007", "dataset": "longevity", "entry_type": "compound", "name": "Alpha-Ketoglutarate (AKG)", "category": "TCA cycle intermediate", "goal": null, "mechanisms": ["TCA cycle substrate — mitochondrial energy", "Prolyl hydroxylase substrate → HIF-1α regulation", "Epigenetic regulation via α-KG dependent dioxygenases (TET, JHDM)", "Anti-inflammatory", "Collagen synthesis support (prolyl hydroxylase)", "mTOR inhibition (modest)"], "primary_effects": [], "dosing_summary": "{\"form\": \"CaAKG preferred\", \"frequency\": \"daily\", \"standard_mg\": \"1000-3000\"}", "safety_summary": "{\"side_effects\": [\"GI upset at high doses\"], \"toxicity\": \"very low — endogenous metabolite\"}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"328-50-7\", \"category\": \"TCA cycle intermediate\", \"dosing\": {\"form\": \"CaAKG preferred\", \"frequency\": \"daily\", \"standard_mg\": \"1000-3000\"}, \"forms\": [\"Calcium AKG (CaAKG)\", \"Arginine AKG\"], \"id\": \"LON-007\", \"longevity_evidence\": {\"biomarker_trial\": \"human trial on methylation clocks\", \"mouse_study\": \"Maksim Khvorova / UCLA — 12% median lifespan extension, health parameters improved\", \"pubmed_ids\": [\"33971272\"]}, \"mechanisms\": [\"TCA cycle substrate — mitochondrial energy\", \"Prolyl hydroxylase substrate → HIF-1α regulation\", \"Epigenetic regulation via α-KG dependent dioxygenases (TET, JHDM)\", \"Anti-inflammatory\", \"Collagen synthesis support (prolyl hydroxylase)\", \"mTOR inhibition (modest)\"], \"name\": \"Alpha-Ketoglutarate (AKG)\", \"safety\": {\"side_effects\": [\"GI upset at high doses\"], \"toxicity\": \"very low — endogenous metabolite\"}, \"synergistic_stack\": [{\"compound\": \"NMN\", \"effect\": \"mitochondrial + epigenetic comprehensive\"}, {\"compound\": \"Rapamycin\", \"effect\": \"multi-pathway longevity\"}]}"}
{"record_id": "LON-008", "dataset": "longevity", "entry_type": "compound", "name": "Urolithin A", "category": "mitophagy inducer", "goal": null, "mechanisms": ["Mitophagy induction (selective autophagy of damaged mitochondria)", "Mitochondrial biogenesis", "NF-κB inhibition", "AMPK activation", "Muscle function improvement"], "primary_effects": [], "dosing_summary": "{\"form\": \"Mitopure (Amazentis) — standardized urolithin A\", \"frequency\": \"daily\", \"note\": \"Only ~40% of people have gut bacteria to produce from food — supplement bypasses this\", \"standard_mg\": \"500-1000\"}", "safety_summary": "{\"side_effects\": [\"mild GI effects\"], \"toxicity\": \"very low\"}", "evidence_level": null, "source_file": "longevity/longevity_database.json", "raw": "{\"cas_number\": \"1143-70-0\", \"category\": \"mitophagy inducer\", \"dosing\": {\"form\": \"Mitopure (Amazentis) — standardized urolithin A\", \"frequency\": \"daily\", \"note\": \"Only ~40% of people have gut bacteria to produce from food — supplement bypasses this\", \"standard_mg\": \"500-1000\"}, \"id\": \"LON-008\", \"longevity_evidence\": {\"human_trial\": \"Amazentis Phase II — muscle function in elderly, safe and effective\", \"pubmed_ids\": [\"31615971\", \"28077374\"], \"worm_data\": \"C. elegans lifespan extension\"}, \"mechanisms\": [\"Mitophagy induction (selective autophagy of damaged mitochondria)\", \"Mitochondrial biogenesis\", \"NF-κB inhibition\", \"AMPK activation\", \"Muscle function improvement\"], \"name\": \"Urolithin A\", \"origin\": \"gut microbiome metabolite of ellagitannins (pomegranate, walnuts)\", \"safety\": {\"side_effects\": [\"mild GI effects\"], \"toxicity\": \"very low\"}}"}
{"record_id": "BM-H001", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Testosterone (Total)", "category": "hormones", "goal": null, "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": "gynecomastia | fatigue | low libido | loss of muscle mass | depression", "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"frequency\": \"every 3-6 months\", \"high_concern_above\": 1100, \"id\": \"BM-H001\", \"key_interactions\": [\"SHBG affects free testosterone\", \"LH indicates cause of low T\", \"E2 balance critical\"], \"low_concern_below\": 400, \"name\": \"Testosterone (Total)\", \"natural_optimization\": [\"resistance training — compound lifts\", \"sleep 7-9h (GH/T axis)\", \"zinc 30-45mg/day\", \"vitamin D 5000IU/day\", \"ashwagandha KSM-66 600mg\", \"reduce cortisol\", \"body fat <20%\", \"fadogia agrestis (preliminary)\", \"tongkat ali (LJ100 extract)\"], \"optimal_biohacker_range\": \"600-900\", \"red_flags\": [\"gynecomastia\", \"fatigue\", \"low libido\", \"loss of muscle mass\", \"depression\"], \"related_biomarkers\": [\"Free T\", \"SHBG\", \"LH\", \"FSH\", \"E2\", \"Prolactin\", \"DHT\"], \"sex\": \"male\", \"standard_lab_range\": \"300-1000\", \"testing_conditions\": \"fasted, morning (7-9am), no exercise 24h prior\", \"unit\": \"ng/dL\"}"}
{"record_id": "BM-H002", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Free Testosterone", "category": "hormones", "goal": "More actionable than total T — bioavailable fraction", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"high_shbg_interventions\": [\"nettle root extract\", \"optimize insulin sensitivity\"], \"id\": \"BM-H002\", \"low_shbg_interventions\": [\"boron 10mg/day reduces SHBG\", \"weight loss\", \"avoid excess alcohol\"], \"name\": \"Free Testosterone\", \"note\": \"More actionable than total T — bioavailable fraction\", \"optimal_biohacker_range\": \"150-250\", \"sex\": \"male\", \"standard_lab_range\": \"47-244\", \"unit\": \"pg/mL\"}"}
{"record_id": "BM-H003", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Estradiol (E2)", "category": "hormones", "goal": "Too low is as bad as too high for males. Critical for bone, libido, cardiovascular.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"high_e2_signs\": [\"water retention\", \"gynecomastia\", \"mood issues\", \"fatigue\"], \"id\": \"BM-H003\", \"low_e2_signs\": [\"joint pain\", \"low libido\", \"brain fog\", \"poor bone density\"], \"name\": \"Estradiol (E2)\", \"natural_optimization\": [\"DIM (diindolylmethane) 200mg — shifts 2-OH pathway\", \"calcium D-glucarate\", \"body fat reduction (aromatase reduction)\", \"cruciferous vegetables\"], \"note\": \"Too low is as bad as too high for males. Critical for bone, libido, cardiovascular.\", \"optimal_biohacker_range\": \"20-30\", \"sex\": \"male\", \"standard_lab_range\": \"10-40\", \"unit\": \"pg/mL\"}"}
{"record_id": "BM-H004", "dataset": "biomarkers", "entry_type": "biomarker", "name": "IGF-1", "category": "hormones", "goal": "TENSION: higher IGF-1 = muscle/performance; lower = longevity (mTOR/cancer). Context matters.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"id\": \"BM-H004\", \"influences\": [\"GH pulsatility\", \"sleep quality\", \"protein intake\", \"insulin sensitivity\", \"liver health\"], \"name\": \"IGF-1\", \"natural_optimization\": [\"optimize sleep — deep sleep GH pulse\", \"GHRP peptides (research)\", \"resistance training\", \"adequate protein 1.6-2.2g/kg\"], \"note\": \"TENSION: higher IGF-1 = muscle/performance; lower = longevity (mTOR/cancer). Context matters.\", \"optimal_biohacker_range_longevity\": \"120-180\", \"optimal_biohacker_range_performance\": \"200-300\", \"sex\": \"both\", \"standard_lab_range\": \"100-300\", \"testing\": \"no fasting required\", \"unit\": \"ng/mL\"}"}
{"record_id": "BM-H005", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Cortisol (AM)", "category": "hormones", "goal": null, "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"chronic_high_effects\": [\"muscle catabolism\", \"insulin resistance\", \"hippocampal shrinkage\", \"immune suppression\", \"T3 conversion inhibition\"], \"id\": \"BM-H005\", \"name\": \"Cortisol (AM)\", \"optimal_biohacker_range\": \"10-18\", \"optimization\": [\"ashwagandha (strongest evidence)\", \"rhodiola rosea\", \"phosphatidylserine 400mg\", \"adequate sleep\", \"HRV biofeedback\", \"cold exposure (acute cortisol, chronic adaptation)\"], \"sex\": \"both\", \"standard_lab_range\": \"6-23\", \"testing_conditions\": \"8am fasted, no exercise prior\", \"unit\": \"mcg/dL\"}"}
{"record_id": "BM-H006", "dataset": "biomarkers", "entry_type": "biomarker", "name": "TSH (Thyroid Stimulating Hormone)", "category": "hormones", "goal": "Standard range too wide. Optimal is lower end.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"complementary_tests\": [\"Free T4\", \"Free T3\", \"Reverse T3\", \"TPO antibodies\", \"thyroglobulin antibodies\"], \"id\": \"BM-H006\", \"low_thyroid_signs\": [\"fatigue\", \"cold intolerance\", \"weight gain\", \"brain fog\", \"hair loss\", \"constipation\"], \"name\": \"TSH (Thyroid Stimulating Hormone)\", \"note\": \"Standard range too wide. Optimal is lower end.\", \"optimal_biohacker_range\": \"0.5-2.0\", \"optimization\": [\"selenium 200mcg (T4→T3 conversion)\", \"iodine (careful — can worsen autoimmune)\", \"zinc\", \"avoid excess soy/goitrogens\", \"ashwagandha (thyroid stimulating)\"], \"standard_lab_range\": \"0.4-4.0\", \"unit\": \"mIU/L\"}"}
{"record_id": "BM-M001", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Fasting Glucose", "category": "metabolic", "goal": "Even 'normal' range upper end associates with increased risk. Optimal is lower.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"id\": \"BM-M001\", \"name\": \"Fasting Glucose\", \"note\": \"Even 'normal' range upper end associates with increased risk. Optimal is lower.\", \"optimal_biohacker_range\": \"72-85\", \"optimization\": [\"time-restricted eating (16:8)\", \"berberine 500mg 3x/day (comparable to metformin)\", \"metformin 500-1000mg (prescription)\", \"resistance training — insulin sensitization\", \"fiber — soluble\", \"apple cider vinegar 1-2tbsp pre-meal\", \"cinnamon extract\"], \"prediabetes\": \"100-125\", \"standard_lab_normal\": \"<100\", \"testing\": \"8-12h fast\", \"unit\": \"mg/dL\"}"}
{"record_id": "BM-M002", "dataset": "biomarkers", "entry_type": "biomarker", "name": "HbA1c", "category": "metabolic", "goal": "3-month average glucose. Best single metabolic marker for longevity.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"id\": \"BM-M002\", \"name\": \"HbA1c\", \"note\": \"3-month average glucose. Best single metabolic marker for longevity.\", \"optimal_biohacker_range\": \"4.8-5.3\", \"optimization\": [\"same as fasting glucose interventions\", \"CGM monitoring for personalized response\"], \"standard_lab_normal\": \"<5.7\", \"unit\": \"%\"}"}
{"record_id": "BM-M003", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Insulin (fasting)", "category": "metabolic", "goal": "Most labs don't flag until >25. Optimal is <6. Hyperinsulinemia is silent.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"high_insulin_effects\": [\"promotes fat storage\", \"mTOR activation\", \"accelerated aging\", \"cancer promotion\", \"cardiovascular risk\"], \"id\": \"BM-M003\", \"name\": \"Insulin (fasting)\", \"note\": \"Most labs don't flag until >25. Optimal is <6. Hyperinsulinemia is silent.\", \"optimal_biohacker_range\": \"2-6\", \"optimization\": [\"time-restricted eating\", \"low-glycemic diet\", \"berberine\", \"resistance training\", \"metformin\", \"avoid snacking — longer fast windows\"], \"standard_lab_normal\": \"<25\", \"unit\": \"μIU/mL\"}"}
{"record_id": "BM-M004", "dataset": "biomarkers", "entry_type": "biomarker", "name": "ApoB", "category": "metabolic", "goal": "Best cardiovascular risk predictor — counts all atherogenic particles. Superior to LDL-C alone.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"id\": \"BM-M004\", \"longevity_target\": \"<60\", \"name\": \"ApoB\", \"note\": \"Best cardiovascular risk predictor — counts all atherogenic particles. Superior to LDL-C alone.\", \"optimal_biohacker_range\": \"<80\", \"optimization\": [\"statins (if indicated)\", \"pcsk9 inhibitors (aggressive)\", \"low-saturated fat diet\", \"omega-3 high dose 4g EPA/DHA\", \"berberine + RYR\", \"exercise\", \"weight loss\"], \"standard_lab_range\": \"<130\", \"unit\": \"mg/dL\"}"}
{"record_id": "BM-M005", "dataset": "biomarkers", "entry_type": "biomarker", "name": "hsCRP (high-sensitivity C-reactive protein)", "category": "metabolic", "goal": "Key inflammaging marker. Even mildly elevated CRP predicts all-cause mortality.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"causes_of_elevation\": [\"metabolic syndrome\", \"gut dysbiosis\", \"sleep apnea\", \"dental disease\", \"food sensitivities\", \"hidden infection\"], \"id\": \"BM-M005\", \"name\": \"hsCRP (high-sensitivity C-reactive protein)\", \"note\": \"Key inflammaging marker. Even mildly elevated CRP predicts all-cause mortality.\", \"optimal_biohacker_range\": \"<0.5\", \"optimization\": [\"omega-3 EPA/DHA 3-4g/day\", \"curcumin + piperine\", \"resolution of gut issues\", \"sleep optimization\", \"exercise\", \"weight loss\", \"dental hygiene\", \"low-AGE diet\"], \"standard_lab_concern\": \">3.0\", \"unit\": \"mg/L\"}"}
{"record_id": "BM-M006", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Homocysteine", "category": "metabolic", "goal": "Cardiovascular + Alzheimer's risk marker. Very modifiable.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"high_causes\": [\"MTHFR polymorphism\", \"B12 deficiency\", \"folate deficiency\", \"B6 deficiency\", \"renal impairment\", \"hypothyroidism\"], \"id\": \"BM-M006\", \"name\": \"Homocysteine\", \"note\": \"Cardiovascular + Alzheimer's risk marker. Very modifiable.\", \"optimal_biohacker_range\": \"6-9\", \"optimization\": [\"methylfolate (5-MTHF) 400-800mcg\", \"methylcobalamin B12 1000mcg\", \"P5P (activated B6) 50-100mg\", \"betaine (TMG) 2-3g\", \"riboflavin (B2)\"], \"standard_lab_normal\": \"<15\", \"unit\": \"μmol/L\"}"}
{"record_id": "BM-N001", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Vitamin D (25-OH)", "category": "micronutrients", "goal": "K2 routes calcium to bones not arteries. Magnesium required for D3 activation.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"cofactors_required\": [\"Vitamin K2 (MK-7) 200mcg\", \"Magnesium 400mg\"], \"id\": \"BM-N001\", \"name\": \"Vitamin D (25-OH)\", \"note\": \"K2 routes calcium to bones not arteries. Magnesium required for D3 activation.\", \"optimal_biohacker_range\": \"60-80\", \"optimization_dose\": {\"deficient_below30\": \"5000-10000 IU/day for 3 months, retest\", \"maintenance_optimal\": \"4000-6000 IU/day\"}, \"standard_lab_sufficient\": \">30\", \"testing_frequency\": \"twice yearly (summer/winter)\", \"unit\": \"ng/mL\", \"upper_tolerable\": 100}"}
{"record_id": "BM-N002", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Magnesium (RBC)", "category": "micronutrients", "goal": "RBC magnesium is far superior to serum — reflects intracellular stores", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"deficiency_prevalence\": \"~45% of population subclinically deficient\", \"dose_mg\": \"300-500 elemental\", \"effects_of_deficiency\": [\"poor sleep\", \"muscle cramps\", \"anxiety\", \"insulin resistance\", \"hypertension\", \"migraines\"], \"forms_and_uses\": {\"L-threonate\": \"brain penetrating — cognitive\", \"citrate\": \"constipation, general\", \"glycinate\": \"sleep, anxiety — best absorbed\", \"malate\": \"energy, fibromyalgia\", \"oxide\": \"avoid — poor absorption\"}, \"id\": \"BM-N002\", \"name\": \"Magnesium (RBC)\", \"note\": \"RBC magnesium is far superior to serum — reflects intracellular stores\", \"optimal_biohacker_range\": \"5.6-6.8\", \"standard_lab_range_RBC\": \"4.2-6.8\", \"unit\": \"mg/dL\"}"}
{"record_id": "BM-N003", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Ferritin", "category": "micronutrients", "goal": "Very low = iron deficiency (energy/cognitive). Very high = oxidative stress, hemochromatosis.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"high_ferritin_concern_above\": 200, \"id\": \"BM-N003\", \"low_concern_below\": 30, \"name\": \"Ferritin\", \"note\": \"Very low = iron deficiency (energy/cognitive). Very high = oxidative stress, hemochromatosis.\", \"optimal_biohacker_range\": \"50-150\", \"optimization_high\": [\"blood donation — most effective\", \"IP6 (inositol hexaphosphate)\", \"reduce heme iron intake\", \"curcumin\"], \"optimization_low\": [\"iron bisglycinate (gentlest form)\", \"vitamin C with iron\", \"address underlying cause\"], \"standard_lab_range\": \"12-300 (male)\", \"unit\": \"ng/mL\"}"}
{"record_id": "BM-N004", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Omega-3 Index", "category": "micronutrients", "goal": null, "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"average_US_population\": \"~4-5%\", \"evidence\": \"among strongest supplements for cardiovascular, brain, inflammation\", \"id\": \"BM-N004\", \"name\": \"Omega-3 Index\", \"optimal_biohacker_range\": \"10-12%\", \"optimization\": {\"dose_grams_EPA_DHA\": \"3-4\", \"form\": \"triglyceride form > ethyl ester\", \"time_to_optimal_months\": 3, \"with_food\": true}, \"standard_low_risk\": \">8%\", \"unit\": \"% EPA+DHA in RBC\"}"}
{"record_id": "BM-A001", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Epigenetic Age (Horvath Clock / DunedinPACE)", "category": "aging_clocks", "goal": null, "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"actionable\": true, \"cost_usd\": \"200-400\", \"frequency\": \"yearly\", \"id\": \"BM-A001\", \"interventions_shown_to_reduce\": [\"exercise (aerobic + resistance)\", \"dietary restriction / caloric restriction\", \"rapamycin\", \"NMN/NR\", \"DHEA\", \"alpha-ketoglutarate (Conboy trial)\", \"plasma exchange (experimental)\"], \"name\": \"Epigenetic Age (Horvath Clock / DunedinPACE)\", \"providers\": [\"TruDiagnostic (TruAge)\", \"Elysium Index\", \"Chronomics\"], \"type\": \"DNA methylation\", \"what_it_measures\": \"Biological age based on methylation patterns at ~350,000 CpG sites\"}"}
{"record_id": "BM-A002", "dataset": "biomarkers", "entry_type": "biomarker", "name": "Telomere Length", "category": "aging_clocks", "goal": "Controversial — high variability between tests. DunedinPACE more actionable.", "mechanisms": [], "primary_effects": [], "dosing_summary": null, "safety_summary": null, "evidence_level": null, "source_file": "biomarkers/biomarkers_database.json", "raw": "{\"id\": \"BM-A002\", \"interventions\": [\"exercise\", \"stress reduction\", \"cycloastragenol (TA-65)\", \"epithalon peptide\"], \"name\": \"Telomere Length\", \"note\": \"Controversial — high variability between tests. DunedinPACE more actionable.\", \"providers\": [\"LifeLength\", \"TeloYears\"], \"type\": \"telomere length measurement\", \"what_it_measures\": \"Average telomere length in leukocytes\"}"}
{"record_id": "PROT-001", "dataset": "protocols", "entry_type": "protocol", "name": "Morning Cognitive Stack", "category": "beginner", "goal": "Peak mental performance, executive function, sustained focus", "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"compounds\": [{\"compound\": \"Modafinil\", \"dose\": \"100mg\", \"note\": \"for high-demand days\", \"optional\": true, \"timing\": \"with breakfast\"}, {\"compound\": \"Alpha-GPC\", \"dose\": \"300mg\", \"timing\": \"AM\"}, {\"compound\": \"Lion's Mane extract\", \"dose\": \"1000mg\", \"timing\": \"AM\"}, {\"compound\": \"Bacopa Monnieri\", \"dose\": \"300mg\", \"timing\": \"with fat\"}, {\"compound\": \"L-Theanine\", \"dose\": \"200mg\", \"timing\": \"with caffeine\"}, {\"compound\": \"Caffeine\", \"dose\": \"100-200mg\", \"timing\": \"AM\"}, {\"compound\": \"Omega-3 EPA/DHA\", \"dose\": \"2g\", \"timing\": \"with food\"}], \"daily_compounds\": [], \"monthly_compounds\": [], \"prescription_additions\": []}", "safety_summary": null, "evidence_level": null, "source_file": "protocols/protocols_database.json", "raw": "{\"compounds\": [{\"compound\": \"Modafinil\", \"dose\": \"100mg\", \"note\": \"for high-demand days\", \"optional\": true, \"timing\": \"with breakfast\"}, {\"compound\": \"Alpha-GPC\", \"dose\": \"300mg\", \"timing\": \"AM\"}, {\"compound\": \"Lion's Mane extract\", \"dose\": \"1000mg\", \"timing\": \"AM\"}, {\"compound\": \"Bacopa Monnieri\", \"dose\": \"300mg\", \"timing\": \"with fat\"}, {\"compound\": \"L-Theanine\", \"dose\": \"200mg\", \"timing\": \"with caffeine\"}, {\"compound\": \"Caffeine\", \"dose\": \"100-200mg\", \"timing\": \"AM\"}, {\"compound\": \"Omega-3 EPA/DHA\", \"dose\": \"2g\", \"timing\": \"with food\"}], \"cost_per_month_usd\": 80, \"difficulty\": \"beginner\", \"expected_effects\": \"2-4 weeks for full effect on memory. Immediate effect on focus (modafinil/caffeine).\", \"goal\": \"Peak mental performance, executive function, sustained focus\", \"id\": \"PROT-001\", \"lifestyle_components\": [\"20-30min exercise before stack (BDNF boost)\", \"Cold shower (norepinephrine boost)\", \"10min meditation or box breathing\", \"No phone first 30 minutes\"], \"name\": \"Morning Cognitive Stack\", \"timing\": \"Morning, fasted or light meal\"}"}
{"record_id": "PROT-002", "dataset": "protocols", "entry_type": "protocol", "name": "Injury Healing Protocol", "category": "intermediate", "goal": "Accelerate healing of tendons, ligaments, muscles, gut", "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"compounds\": [{\"compound\": \"BPC-157\", \"dose\": \"250-500mcg\", \"phase\": \"acute + maintenance\", \"timing\": \"2x daily SC near injury\"}, {\"compound\": \"TB-500\", \"dose\": \"5mg\", \"phase\": \"loading (4 weeks)\", \"timing\": \"2x weekly SC\"}, {\"compound\": \"TB-500\", \"dose\": \"2.5mg\", \"phase\": \"maintenance\", \"timing\": \"2x weekly SC\"}, {\"compound\": \"Vitamin C\", \"dose\": \"2-3g\", \"note\": \"collagen synthesis cofactor\", \"timing\": \"with collagen\"}, {\"compound\": \"Collagen peptides\", \"dose\": \"15g\", \"timing\": \"pre-exercise or daily\"}, {\"compound\": \"Curcumin + piperine\", \"dose\": \"500-1000mg\", \"timing\": \"with fat, daily\"}, {\"compound\": \"GHK-Cu\", \"dose\": \"topical 0.5%\", \"optional\": true, \"timing\": \"on wound/injury surface\"}], \"daily_compounds\": [], \"monthly_compounds\": [], \"prescription_additions\": []}", "safety_summary": null, "evidence_level": null, "source_file": "protocols/protocols_database.json", "raw": "{\"compounds\": [{\"compound\": \"BPC-157\", \"dose\": \"250-500mcg\", \"phase\": \"acute + maintenance\", \"timing\": \"2x daily SC near injury\"}, {\"compound\": \"TB-500\", \"dose\": \"5mg\", \"phase\": \"loading (4 weeks)\", \"timing\": \"2x weekly SC\"}, {\"compound\": \"TB-500\", \"dose\": \"2.5mg\", \"phase\": \"maintenance\", \"timing\": \"2x weekly SC\"}, {\"compound\": \"Vitamin C\", \"dose\": \"2-3g\", \"note\": \"collagen synthesis cofactor\", \"timing\": \"with collagen\"}, {\"compound\": \"Collagen peptides\", \"dose\": \"15g\", \"timing\": \"pre-exercise or daily\"}, {\"compound\": \"Curcumin + piperine\", \"dose\": \"500-1000mg\", \"timing\": \"with fat, daily\"}, {\"compound\": \"GHK-Cu\", \"dose\": \"topical 0.5%\", \"optional\": true, \"timing\": \"on wound/injury surface\"}], \"cost_per_month_usd\": 120, \"difficulty\": \"intermediate\", \"goal\": \"Accelerate healing of tendons, ligaments, muscles, gut\", \"id\": \"PROT-002\", \"lifestyle_components\": [\"Blood flow restriction training (BFR) for injured limb\", \"Adequate protein 1.8-2.2g/kg\", \"Sleep 8h+ — peak GH/repair\", \"Avoid NSAIDs — blunt healing response\"], \"name\": \"Injury Healing Protocol\", \"timeline\": \"Acute injury: noticeable in 2-4 weeks. Chronic injury: 6-12 weeks.\"}"}
{"record_id": "PROT-003", "dataset": "protocols", "entry_type": "protocol", "name": "Testosterone Optimization (Natural)", "category": "beginner", "goal": "Maximize endogenous testosterone production without exogenous hormones", "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"compounds\": [{\"compound\": \"Ashwagandha KSM-66\", \"dose\": \"600mg\", \"timing\": \"evening with food\"}, {\"compound\": \"Zinc\", \"dose\": \"30mg bisglycinate\", \"timing\": \"evening\"}, {\"compound\": \"Magnesium glycinate\", \"dose\": \"400mg\", \"timing\": \"before bed\"}, {\"compound\": \"Vitamin D3\", \"dose\": \"5000IU\", \"timing\": \"morning with K2\"}, {\"compound\": \"Vitamin K2 MK-7\", \"dose\": \"200mcg\", \"timing\": \"with D3\"}, {\"compound\": \"Boron\", \"dose\": \"10mg\", \"note\": \"reduces SHBG\", \"timing\": \"daily\"}, {\"compound\": \"Fadogia Agrestis\", \"dose\": \"600mg\", \"note\": \"LH stimulation — preliminary data\", \"timing\": \"daily\"}, {\"compound\": \"Tongkat Ali LJ100\", \"dose\": \"200mg\", \"note\": \"SHBG reduction, LH\", \"timing\": \"AM\"}, {\"compound\": \"DIM\", \"dose\": \"200mg\", \"note\": \"estrogen metabolism optimization\", \"timing\": \"daily\"}], \"daily_compounds\": [], \"monthly_compounds\": [], \"prescription_additions\": []}", "safety_summary": null, "evidence_level": null, "source_file": "protocols/protocols_database.json", "raw": "{\"compounds\": [{\"compound\": \"Ashwagandha KSM-66\", \"dose\": \"600mg\", \"timing\": \"evening with food\"}, {\"compound\": \"Zinc\", \"dose\": \"30mg bisglycinate\", \"timing\": \"evening\"}, {\"compound\": \"Magnesium glycinate\", \"dose\": \"400mg\", \"timing\": \"before bed\"}, {\"compound\": \"Vitamin D3\", \"dose\": \"5000IU\", \"timing\": \"morning with K2\"}, {\"compound\": \"Vitamin K2 MK-7\", \"dose\": \"200mcg\", \"timing\": \"with D3\"}, {\"compound\": \"Boron\", \"dose\": \"10mg\", \"note\": \"reduces SHBG\", \"timing\": \"daily\"}, {\"compound\": \"Fadogia Agrestis\", \"dose\": \"600mg\", \"note\": \"LH stimulation — preliminary data\", \"timing\": \"daily\"}, {\"compound\": \"Tongkat Ali LJ100\", \"dose\": \"200mg\", \"note\": \"SHBG reduction, LH\", \"timing\": \"AM\"}, {\"compound\": \"DIM\", \"dose\": \"200mg\", \"note\": \"estrogen metabolism optimization\", \"timing\": \"daily\"}], \"cost_per_month_usd\": 90, \"difficulty\": \"beginner\", \"expected_increase\": \"20-40% in clinically low individuals. Less in already-optimal.\", \"goal\": \"Maximize endogenous testosterone production without exogenous hormones\", \"id\": \"PROT-003\", \"lifestyle_components\": [\"Compound lifting 4x/week (squats, deadlifts, bench)\", \"Sprint intervals 1-2x/week\", \"Sleep 8h — testosterone peaks in deep sleep\", \"Body fat <15%\", \"Reduce chronic stress — cortisol antagonizes T\", \"Sauna 3-4x/week (heat shock proteins, testicular cooling after)\"], \"monitoring\": \"Test total T, free T, E2, LH, FSH at baseline and 3 months\", \"name\": \"Testosterone Optimization (Natural)\"}"}
{"record_id": "PROT-004", "dataset": "protocols", "entry_type": "protocol", "name": "Longevity Core Stack (Bryan Johnson inspired)", "category": "advanced", "goal": "Comprehensive hallmarks of aging coverage for healthspan extension", "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"compounds\": [], \"daily_compounds\": [{\"compound\": \"NMN\", \"dose\": \"500-1000mg\", \"timing\": \"morning sublingual\"}, {\"compound\": \"Resveratrol\", \"dose\": \"1000mg\", \"timing\": \"morning with fat (Sinclair protocol)\"}, {\"compound\": \"TMG (Trimethylglycine)\", \"dose\": \"1000mg\", \"note\": \"methyl donor\", \"timing\": \"morning\"}, {\"compound\": \"Spermidine\", \"dose\": \"3mg\", \"timing\": \"daily\"}, {\"compound\": \"Alpha-Ketoglutarate (CaAKG)\", \"dose\": \"1500mg\", \"timing\": \"daily\"}, {\"compound\": \"Urolithin A (Mitopure)\", \"dose\": \"500mg\", \"timing\": \"daily\"}, {\"compound\": \"Fisetin\", \"dose\": \"100mg\", \"timing\": \"daily\"}, {\"compound\": \"Quercetin\", \"dose\": \"500mg\", \"timing\": \"daily\"}, {\"compound\": \"Omega-3 EPA/DHA\", \"dose\": \"3g\", \"timing\": \"with food\"}, {\"compound\": \"Vitamin D3\", \"dose\": \"5000IU\", \"timing\": \"morning\"}, {\"compound\": \"K2 MK-7\", \"dose\": \"200mcg\", \"timing\": \"with D3\"}, {\"compound\": \"Magnesium L-threonate\", \"dose\": \"2g\", \"timing\": \"evening\"}], \"monthly_compounds\": [{\"compound\": \"Fisetin\", \"dose\": \"1500mg x 2 days\", \"frequency\": \"monthly senolytic pulse\", \"note\": \"higher dose senolytic protocol\"}], \"prescription_additions\": [{\"compound\": \"Rapamycin\", \"dose\": \"5-6mg\", \"frequency\": \"once weekly\", \"note\": \"off-label — physician required\"}, {\"caveat\": \"may blunt exercise — consider cycling off on training days\", \"compound\": \"Metformin XR\", \"dose\": \"500-1000mg\", \"frequency\": \"daily\", \"note\": \"off-label — physician required\"}]}", "safety_summary": null, "evidence_level": null, "source_file": "protocols/protocols_database.json", "raw": "{\"cost_per_month_usd_supplements\": 300, \"daily_compounds\": [{\"compound\": \"NMN\", \"dose\": \"500-1000mg\", \"timing\": \"morning sublingual\"}, {\"compound\": \"Resveratrol\", \"dose\": \"1000mg\", \"timing\": \"morning with fat (Sinclair protocol)\"}, {\"compound\": \"TMG (Trimethylglycine)\", \"dose\": \"1000mg\", \"note\": \"methyl donor\", \"timing\": \"morning\"}, {\"compound\": \"Spermidine\", \"dose\": \"3mg\", \"timing\": \"daily\"}, {\"compound\": \"Alpha-Ketoglutarate (CaAKG)\", \"dose\": \"1500mg\", \"timing\": \"daily\"}, {\"compound\": \"Urolithin A (Mitopure)\", \"dose\": \"500mg\", \"timing\": \"daily\"}, {\"compound\": \"Fisetin\", \"dose\": \"100mg\", \"timing\": \"daily\"}, {\"compound\": \"Quercetin\", \"dose\": \"500mg\", \"timing\": \"daily\"}, {\"compound\": \"Omega-3 EPA/DHA\", \"dose\": \"3g\", \"timing\": \"with food\"}, {\"compound\": \"Vitamin D3\", \"dose\": \"5000IU\", \"timing\": \"morning\"}, {\"compound\": \"K2 MK-7\", \"dose\": \"200mcg\", \"timing\": \"with D3\"}, {\"compound\": \"Magnesium L-threonate\", \"dose\": \"2g\", \"timing\": \"evening\"}], \"difficulty\": \"advanced\", \"goal\": \"Comprehensive hallmarks of aging coverage for healthspan extension\", \"id\": \"PROT-004\", \"lifestyle_non_negotiables\": [\"Zone 2 cardio 4h/week\", \"VO2max training 1-2x/week\", \"Resistance training 3x/week\", \"Sleep 8h — prioritize deep + REM\", \"Time-restricted eating 16:8\", \"Sauna 4x/week 20min\", \"Cold exposure 2-3min\", \"Continuous glucose monitoring (CGM)\", \"Annual bloodwork panel + epigenetic age test\"], \"monthly_compounds\": [{\"compound\": \"Fisetin\", \"dose\": \"1500mg x 2 days\", \"frequency\": \"monthly senolytic pulse\", \"note\": \"higher dose senolytic protocol\"}], \"name\": \"Longevity Core Stack (Bryan Johnson inspired)\", \"note\": \"Conservative version — consult physician before rapamycin/metformin\", \"prescription_additions\": [{\"compound\": \"Rapamycin\", \"dose\": \"5-6mg\", \"frequency\": \"once weekly\", \"note\": \"off-label — physician required\"}, {\"caveat\": \"may blunt exercise — consider cycling off on training days\", \"compound\": \"Metformin XR\", \"dose\": \"500-1000mg\", \"frequency\": \"daily\", \"note\": \"off-label — physician required\"}]}"}
{"record_id": "PROT-005", "dataset": "protocols", "entry_type": "protocol", "name": "GH Optimization Stack", "category": "advanced", "goal": "Maximize endogenous GH pulsatility, IGF-1, body composition", "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"compounds\": [{\"compound\": \"CJC-1295 (with DAC)\", \"dose\": \"1000mcg\", \"note\": \"GHRH analogue\", \"timing\": \"2x weekly SC\"}, {\"compound\": \"Ipamorelin\", \"dose\": \"300mcg\", \"note\": \"GHRP — cleanest\", \"timing\": \"3x daily SC — AM, pre-workout, before bed\"}, {\"compound\": \"MK-677 (Ibutamoren)\", \"dose\": \"12.5-25mg\", \"note\": \"oral ghrelin mimetic — alternative to injectables\", \"timing\": \"before bed oral\"}, {\"compound\": \"Zinc\", \"dose\": \"30mg\", \"timing\": \"daily\"}, {\"compound\": \"Vitamin D3\", \"dose\": \"5000IU\", \"timing\": \"daily\"}, {\"compound\": \"Magnesium glycinate\", \"dose\": \"400mg\", \"timing\": \"before bed\"}], \"daily_compounds\": [], \"monthly_compounds\": [], \"prescription_additions\": []}", "safety_summary": null, "evidence_level": null, "source_file": "protocols/protocols_database.json", "raw": "{\"compounds\": [{\"compound\": \"CJC-1295 (with DAC)\", \"dose\": \"1000mcg\", \"note\": \"GHRH analogue\", \"timing\": \"2x weekly SC\"}, {\"compound\": \"Ipamorelin\", \"dose\": \"300mcg\", \"note\": \"GHRP — cleanest\", \"timing\": \"3x daily SC — AM, pre-workout, before bed\"}, {\"compound\": \"MK-677 (Ibutamoren)\", \"dose\": \"12.5-25mg\", \"note\": \"oral ghrelin mimetic — alternative to injectables\", \"timing\": \"before bed oral\"}, {\"compound\": \"Zinc\", \"dose\": \"30mg\", \"timing\": \"daily\"}, {\"compound\": \"Vitamin D3\", \"dose\": \"5000IU\", \"timing\": \"daily\"}, {\"compound\": \"Magnesium glycinate\", \"dose\": \"400mg\", \"timing\": \"before bed\"}], \"cost_per_month_usd\": 150, \"cycle\": \"12-16 weeks on, 4 weeks off\", \"difficulty\": \"advanced\", \"goal\": \"Maximize endogenous GH pulsatility, IGF-1, body composition\", \"id\": \"PROT-005\", \"lifestyle_components\": [\"Fasted cardio — GH peaks fasted\", \"Heavy compound training\", \"Sleep optimization — peak GH in first 90min\", \"Avoid carbs 2h pre-bed injection\", \"Intermittent fasting\"], \"monitoring\": [\"IGF-1 baseline and monthly\", \"glucose/insulin (MK-677 can raise)\", \"fasting insulin\"], \"name\": \"GH Optimization Stack\", \"note\": \"Research peptides — gray market. Educational purposes.\"}"}
{"record_id": "PROT-006", "dataset": "protocols", "entry_type": "protocol", "name": "Sleep & Recovery Protocol", "category": "beginner", "goal": "Deep sleep optimization, HRV improvement, overnight recovery", "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"compounds\": [{\"compound\": \"Magnesium glycinate\", \"dose\": \"400mg\", \"timing\": \"1h before bed\"}, {\"compound\": \"Glycine\", \"dose\": \"3g\", \"note\": \"reduces core body temp, improves deep sleep\", \"timing\": \"30min before bed\"}, {\"compound\": \"L-theanine\", \"dose\": \"200mg\", \"timing\": \"30min before bed\"}, {\"compound\": \"Ashwagandha KSM-66\", \"dose\": \"300mg\", \"timing\": \"evening\"}, {\"compound\": \"Melatonin\", \"dose\": \"0.3-1mg\", \"note\": \"lower dose more physiological — avoid 5-10mg\", \"timing\": \"2h before target sleep\"}, {\"compound\": \"Apigenin\", \"dose\": \"50mg\", \"note\": \"chamomile-derived, GABA-A modulation\", \"timing\": \"30min before bed\"}, {\"compound\": \"Phosphatidylserine\", \"dose\": \"400mg\", \"note\": \"blunts evening cortisol spike\", \"timing\": \"evening\"}], \"daily_compounds\": [], \"monthly_compounds\": [], \"prescription_additions\": []}", "safety_summary": null, "evidence_level": null, "source_file": "protocols/protocols_database.json", "raw": "{\"compounds\": [{\"compound\": \"Magnesium glycinate\", \"dose\": \"400mg\", \"timing\": \"1h before bed\"}, {\"compound\": \"Glycine\", \"dose\": \"3g\", \"note\": \"reduces core body temp, improves deep sleep\", \"timing\": \"30min before bed\"}, {\"compound\": \"L-theanine\", \"dose\": \"200mg\", \"timing\": \"30min before bed\"}, {\"compound\": \"Ashwagandha KSM-66\", \"dose\": \"300mg\", \"timing\": \"evening\"}, {\"compound\": \"Melatonin\", \"dose\": \"0.3-1mg\", \"note\": \"lower dose more physiological — avoid 5-10mg\", \"timing\": \"2h before target sleep\"}, {\"compound\": \"Apigenin\", \"dose\": \"50mg\", \"note\": \"chamomile-derived, GABA-A modulation\", \"timing\": \"30min before bed\"}, {\"compound\": \"Phosphatidylserine\", \"dose\": \"400mg\", \"note\": \"blunts evening cortisol spike\", \"timing\": \"evening\"}], \"cost_per_month_usd\": 60, \"difficulty\": \"beginner\", \"goal\": \"Deep sleep optimization, HRV improvement, overnight recovery\", \"id\": \"PROT-006\", \"lifestyle_components\": [\"Dark room + cold (18°C/65°F) — core body temp reduction\", \"No blue light 2h before bed (or blue-blockers)\", \"Last meal 3h before sleep\", \"Consistent sleep/wake time — circadian anchoring\", \"Morning sunlight 10-20min\", \"No alcohol (fragments sleep architecture)\", \"Oura ring or WHOOP for HRV monitoring\"], \"name\": \"Sleep & Recovery Protocol\"}"}
{"record_id": "NUT-001", "dataset": "nutrition", "entry_type": "dietary_strategy", "name": "Time-Restricted Eating (TRE)", "category": "dietary_strategy", "goal": "Autophagy induction (16h+ fasting) | Insulin sensitivity improvement | mTOR suppression during fast | Circadian rhythm alignment | Weight management | Reduced inflammation", "mechanisms": [], "primary_effects": ["Autophagy induction (16h+ fasting)", "Insulin sensitivity improvement", "mTOR suppression during fast", "Circadian rhythm alignment", "Weight management", "Reduced inflammation"], "dosing_summary": "[{\"difficulty\": \"easy\", \"eating_window_hours\": 8, \"evidence\": \"strong\", \"fast_hours\": 16, \"name\": \"16:8\"}, {\"difficulty\": \"moderate\", \"eating_window_hours\": 6, \"evidence\": \"strong\", \"fast_hours\": 18, \"name\": \"18:6\"}, {\"difficulty\": \"hard\", \"eating_window_hours\": 1, \"evidence\": \"moderate\", \"fast_hours\": 23, \"name\": \"OMAD (One Meal A Day)\"}, {\"description\": \"5 normal days, 2 days at 500-600 kcal\", \"difficulty\": \"moderate\", \"evidence\": \"moderate\", \"name\": \"5:2\"}]", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"autophagy_threshold_hours\": 16, \"benefits\": [\"Autophagy induction (16h+ fasting)\", \"Insulin sensitivity improvement\", \"mTOR suppression during fast\", \"Circadian rhythm alignment\", \"Weight management\", \"Reduced inflammation\"], \"id\": \"NUT-001\", \"key_rules\": [\"Coffee/tea (no calories) allowed in fast\", \"Break fast with protein + fat, not carbs (insulin management)\", \"Electrolytes during extended fasts\", \"Adjust protein timing — prioritize post-training\"], \"name\": \"Time-Restricted Eating (TRE)\", \"optimal_window\": \"earlier in day (8am-4pm) aligns with circadian biology — superior metabolic outcomes vs late eating\", \"protocols\": [{\"difficulty\": \"easy\", \"eating_window_hours\": 8, \"evidence\": \"strong\", \"fast_hours\": 16, \"name\": \"16:8\"}, {\"difficulty\": \"moderate\", \"eating_window_hours\": 6, \"evidence\": \"strong\", \"fast_hours\": 18, \"name\": \"18:6\"}, {\"difficulty\": \"hard\", \"eating_window_hours\": 1, \"evidence\": \"moderate\", \"fast_hours\": 23, \"name\": \"OMAD (One Meal A Day)\"}, {\"description\": \"5 normal days, 2 days at 500-600 kcal\", \"difficulty\": \"moderate\", \"evidence\": \"moderate\", \"name\": \"5:2\"}]}"}
{"record_id": "NUT-002", "dataset": "nutrition", "entry_type": "dietary_strategy", "name": "Protein Optimization", "category": "dietary_strategy", "goal": null, "mechanisms": [], "primary_effects": [], "dosing_summary": "{\"leucine_threshold_g_per_meal\": 2.5, \"max_beneficial_g_per_kg\": 2.2, \"meal_frequency_for_mps\": \"3-4 meals with 30-40g protein each\", \"minimum_muscle_preservation_g_per_kg\": 1.6, \"optimal_muscle_building_g_per_kg\": 2.0}", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"id\": \"NUT-002\", \"name\": \"Protein Optimization\", \"sources_ranked\": [{\"digestibility_DIAAS\": 1.25, \"leucine_percent\": 11, \"notes\": \"fastest absorption, highest leucine\", \"source\": \"Whey isolate\"}, {\"digestibility_DIAAS\": 1.22, \"leucine_percent\": 9, \"notes\": \"slow release, ideal pre-bed\", \"source\": \"Casein\"}, {\"digestibility_DIAAS\": 1.13, \"leucine_percent\": 8.5, \"notes\": \"complete, high bioavailability\", \"source\": \"Eggs (whole)\"}, {\"digestibility_DIAAS\": 1.14, \"leucine_percent\": 8, \"notes\": \"creatine, B12, zinc bonus\", \"source\": \"Beef\"}, {\"digestibility_DIAAS\": 1.0, \"leucine_percent\": 8, \"notes\": \"omega-3, astaxanthin bonus\", \"source\": \"Salmon\"}, {\"digestibility_DIAAS\": 0.98, \"leucine_percent\": 7.5, \"notes\": \"best plant option\", \"source\": \"Soy isolate\"}, {\"digestibility_DIAAS\": 0.6, \"leucine_percent\": 6, \"notes\": \"combine with rice for complete AA\", \"source\": \"Legumes\"}], \"targets\": {\"leucine_threshold_g_per_meal\": 2.5, \"max_beneficial_g_per_kg\": 2.2, \"meal_frequency_for_mps\": \"3-4 meals with 30-40g protein each\", \"minimum_muscle_preservation_g_per_kg\": 1.6, \"optimal_muscle_building_g_per_kg\": 2.0}, \"timing\": {\"post_workout_window_minutes\": 60, \"pre_bed_casein\": \"40g casein = 25-30% better overnight MPS\", \"pre_workout\": \"20-40g protein 1-2h pre improves performance\"}}"}
{"record_id": "NUT-003", "dataset": "nutrition", "entry_type": "dietary_strategy", "name": "Ketogenic Diet for Performance & Cognition", "category": "dietary_strategy", "goal": "Ketone bodies (BHB) — cleaner brain fuel | Reduced neuroinflammation | Metabolic flexibility | Appetite suppression (ghrelin reduction) | mTOR pulsatility vs chronic activation", "mechanisms": [], "primary_effects": ["Ketone bodies (BHB) — cleaner brain fuel", "Reduced neuroinflammation", "Metabolic flexibility", "Appetite suppression (ghrelin reduction)", "mTOR pulsatility vs chronic activation"], "dosing_summary": "{}", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"adaptation_period_weeks\": \"2-6 (keto flu during transition)\", \"benefits\": [\"Ketone bodies (BHB) — cleaner brain fuel\", \"Reduced neuroinflammation\", \"Metabolic flexibility\", \"Appetite suppression (ghrelin reduction)\", \"mTOR pulsatility vs chronic activation\"], \"carb_threshold_g\": 20, \"exogenous_ketones\": {\"limitation\": \"BHB salts — large sodium load; esters — expensive, strong taste\", \"type\": \"BHB salts or esters\", \"use_case\": \"acute cognitive performance before keto-adaptation\"}, \"id\": \"NUT-003\", \"ketosis_threshold_mmol\": 0.5, \"macros_percent\": {\"carbs\": 5, \"fat\": 70, \"protein\": 25}, \"name\": \"Ketogenic Diet for Performance & Cognition\", \"nutritional_ketosis_range_mmol\": \"0.5-3.0\", \"supplements_during_adaptation\": [{\"compound\": \"Sodium\", \"dose_mg\": 2000, \"note\": \"increased excretion on keto\"}, {\"compound\": \"Potassium\", \"dose_mg\": 3000}, {\"compound\": \"Magnesium\", \"dose_mg\": 400}, {\"compound\": \"MCT oil\", \"dose_g\": \"10-30\", \"note\": \"rapid ketone source, GI tolerance required\"}]}"}
{"record_id": "NUT-MICRO-omega-3-(epa/dha)", "dataset": "nutrition", "entry_type": "micronutrient", "name": "Omega-3 (EPA/DHA)", "category": "micronutrient", "goal": "anti-inflammatory | cardiovascular | brain structure | insulin sensitivity | cortisol reduction", "mechanisms": [], "primary_effects": ["anti-inflammatory", "cardiovascular", "brain structure", "insulin sensitivity", "cortisol reduction"], "dosing_summary": "{\"benefits\": [\"anti-inflammatory\", \"cardiovascular\", \"brain structure\", \"insulin sensitivity\", \"cortisol reduction\"], \"best_sources\": [\"sardines\", \"mackerel\", \"wild salmon\", \"anchovies\", \"fish oil triglyceride form\"], \"nutrient\": \"Omega-3 (EPA/DHA)\", \"omega3_index_target_percent\": \"10-12\", \"optimal_intake_g_EPA_DHA\": \"3-4\", \"ratio_note\": \"Western diet EPA:DHA ratio often 1:3 (bad) — target closer to 1:1 or 2:1 EPA:DHA\"}", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"benefits\": [\"anti-inflammatory\", \"cardiovascular\", \"brain structure\", \"insulin sensitivity\", \"cortisol reduction\"], \"best_sources\": [\"sardines\", \"mackerel\", \"wild salmon\", \"anchovies\", \"fish oil triglyceride form\"], \"nutrient\": \"Omega-3 (EPA/DHA)\", \"omega3_index_target_percent\": \"10-12\", \"optimal_intake_g_EPA_DHA\": \"3-4\", \"ratio_note\": \"Western diet EPA:DHA ratio often 1:3 (bad) — target closer to 1:1 or 2:1 EPA:DHA\"}"}
{"record_id": "NUT-MICRO-creatine-monohydrate", "dataset": "nutrition", "entry_type": "micronutrient", "name": "Creatine Monohydrate", "category": "micronutrient", "goal": "strength +5-15% | cognitive function (esp. vegetarians) | creatine kinase buffering | neuroprotection | anti-aging", "mechanisms": [], "primary_effects": ["strength +5-15%", "cognitive function (esp. vegetarians)", "creatine kinase buffering", "neuroprotection", "anti-aging"], "dosing_summary": "{\"benefits\": [\"strength +5-15%\", \"cognitive function (esp. vegetarians)\", \"creatine kinase buffering\", \"neuroprotection\", \"anti-aging\"], \"cost_per_month_usd\": 5, \"dose_g\": 5, \"evidence_level\": \"extremely strong — one of most studied supplements\", \"form\": \"creatine monohydrate — original, best studied\", \"frequency\": \"daily\", \"loading\": \"optional: 20g/day x 5 days then 5g maintenance\", \"nutrient\": \"Creatine Monohydrate\"}", "safety_summary": null, "evidence_level": "extremely strong — one of most studied supplements", "source_file": "nutrition/nutrition_database.json", "raw": "{\"benefits\": [\"strength +5-15%\", \"cognitive function (esp. vegetarians)\", \"creatine kinase buffering\", \"neuroprotection\", \"anti-aging\"], \"cost_per_month_usd\": 5, \"dose_g\": 5, \"evidence_level\": \"extremely strong — one of most studied supplements\", \"form\": \"creatine monohydrate — original, best studied\", \"frequency\": \"daily\", \"loading\": \"optional: 20g/day x 5 days then 5g maintenance\", \"nutrient\": \"Creatine Monohydrate\"}"}
{"record_id": "NUT-MICRO-berberine", "dataset": "nutrition", "entry_type": "micronutrient", "name": "Berberine", "category": "micronutrient", "goal": "blood glucose comparable to metformin in T2D | LDL -25% | triglycerides -35% | weight loss", "mechanisms": ["AMPK activation (like metformin)", "gut microbiome modulation", "PCSK9 inhibition (lipids)", "anti-inflammatory"], "primary_effects": ["blood glucose comparable to metformin in T2D", "LDL -25%", "triglycerides -35%", "weight loss"], "dosing_summary": "{\"benefits\": [\"blood glucose comparable to metformin in T2D\", \"LDL -25%\", \"triglycerides -35%\", \"weight loss\"], \"dose_mg\": \"500 3x/day (1500 total)\", \"evidence_level\": \"strong\", \"mechanisms\": [\"AMPK activation (like metformin)\", \"gut microbiome modulation\", \"PCSK9 inhibition (lipids)\", \"anti-inflammatory\"], \"note\": \"Half-life 4-6h — require multiple doses. Dihydroberberine (DHB) = higher bioavailability, lower dose\", \"nutrient\": \"Berberine\", \"timing\": \"with meals\"}", "safety_summary": null, "evidence_level": "strong", "source_file": "nutrition/nutrition_database.json", "raw": "{\"benefits\": [\"blood glucose comparable to metformin in T2D\", \"LDL -25%\", \"triglycerides -35%\", \"weight loss\"], \"dose_mg\": \"500 3x/day (1500 total)\", \"evidence_level\": \"strong\", \"mechanisms\": [\"AMPK activation (like metformin)\", \"gut microbiome modulation\", \"PCSK9 inhibition (lipids)\", \"anti-inflammatory\"], \"note\": \"Half-life 4-6h — require multiple doses. Dihydroberberine (DHB) = higher bioavailability, lower dose\", \"nutrient\": \"Berberine\", \"timing\": \"with meals\"}"}
{"record_id": "NUT-MICRO-curcumin-+-piperine", "dataset": "nutrition", "entry_type": "micronutrient", "name": "Curcumin + Piperine", "category": "micronutrient", "goal": null, "mechanisms": ["NF-κB inhibition", "COX-2 inhibition", "BDNF upregulation", "autophagy", "epigenetic"], "primary_effects": [], "dosing_summary": "{\"dose_mg_curcumin\": \"500-1000\", \"evidence_level\": \"strong for inflammation, moderate for other claims\", \"form\": \"liposomal or phosphatidylcholine complex for best absorption\", \"mechanisms\": [\"NF-κB inhibition\", \"COX-2 inhibition\", \"BDNF upregulation\", \"autophagy\", \"epigenetic\"], \"nutrient\": \"Curcumin + Piperine\", \"piperine_enhances_bioavailability_x\": 20}", "safety_summary": null, "evidence_level": "strong for inflammation, moderate for other claims", "source_file": "nutrition/nutrition_database.json", "raw": "{\"dose_mg_curcumin\": \"500-1000\", \"evidence_level\": \"strong for inflammation, moderate for other claims\", \"form\": \"liposomal or phosphatidylcholine complex for best absorption\", \"mechanisms\": [\"NF-κB inhibition\", \"COX-2 inhibition\", \"BDNF upregulation\", \"autophagy\", \"epigenetic\"], \"nutrient\": \"Curcumin + Piperine\", \"piperine_enhances_bioavailability_x\": 20}"}
{"record_id": "NUT-SNP-MTHFR-C677T", "dataset": "nutrition", "entry_type": "nutrigenomics_snp", "name": "MTHFR C677T", "category": "nutrigenomics", "goal": "elevated homocysteine | reduced SAM (methylation) | potential B12/folate deficiency despite 'normal' labs", "mechanisms": [], "primary_effects": ["elevated homocysteine", "reduced SAM (methylation)", "potential B12/folate deficiency despite 'normal' labs"], "dosing_summary": "Methylfolate (5-MTHF) not folic acid | Methylcobalamin not cyanocobalamin | Betaine (TMG) 1-3g/day | Monitor homocysteine", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"effect\": \"Reduced methylenetetrahydrofolate reductase activity — impaired folate metabolism\", \"gene\": \"MTHFR\", \"implications\": [\"elevated homocysteine\", \"reduced SAM (methylation)\", \"potential B12/folate deficiency despite 'normal' labs\"], \"interventions\": [\"Methylfolate (5-MTHF) not folic acid\", \"Methylcobalamin not cyanocobalamin\", \"Betaine (TMG) 1-3g/day\", \"Monitor homocysteine\"], \"population_frequency_percent\": 40, \"variant\": \"C677T\"}"}
{"record_id": "NUT-SNP-APOE-ε4", "dataset": "nutrition", "entry_type": "nutrigenomics_snp", "name": "APOE ε4", "category": "nutrigenomics", "goal": "saturated fat → higher LDL response | omega-3 even more important | DHA uptake reduced", "mechanisms": [], "primary_effects": ["saturated fat → higher LDL response", "omega-3 even more important", "DHA uptake reduced"], "dosing_summary": "Higher omega-3 DHA supplementation | Reduce saturated fat (stronger response vs non-ε4) | Earlier cognitive interventions | Lion's Mane, Bacopa — neuroprotective priority", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"effect\": \"Increased Alzheimer's risk, altered lipid metabolism\", \"gene\": \"APOE\", \"implications\": [\"saturated fat → higher LDL response\", \"omega-3 even more important\", \"DHA uptake reduced\"], \"interventions\": [\"Higher omega-3 DHA supplementation\", \"Reduce saturated fat (stronger response vs non-ε4)\", \"Earlier cognitive interventions\", \"Lion's Mane, Bacopa — neuroprotective priority\"], \"population_frequency_percent\": 25, \"variant\": \"ε4\"}"}
{"record_id": "NUT-SNP-VDR-multiple", "dataset": "nutrition", "entry_type": "nutrigenomics_snp", "name": "VDR multiple", "category": "nutrigenomics", "goal": "need higher D3 doses for same effect", "mechanisms": [], "primary_effects": ["need higher D3 doses for same effect"], "dosing_summary": "Target higher 25-OH D3 levels (80-100ng/mL vs 60-80)", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"effect\": \"Vitamin D receptor polymorphisms — reduced signaling\", \"gene\": \"VDR\", \"implications\": [\"need higher D3 doses for same effect\"], \"interventions\": [\"Target higher 25-OH D3 levels (80-100ng/mL vs 60-80)\"], \"variant\": \"multiple\"}"}
{"record_id": "NUT-SNP-CYP1A2-rs762551", "dataset": "nutrition", "entry_type": "nutrigenomics_snp", "name": "CYP1A2 rs762551", "category": "nutrigenomics", "goal": null, "mechanisms": [], "primary_effects": [], "dosing_summary": "Slow metabolizers: limit caffeine to 1-2 cups, no afternoon caffeine", "safety_summary": null, "evidence_level": null, "source_file": "nutrition/nutrition_database.json", "raw": "{\"effect\": \"Caffeine metabolism speed\", \"fast_metabolizers\": \"1A allele — caffeine cleared quickly, cardiovascular protective\", \"gene\": \"CYP1A2\", \"interventions\": [\"Slow metabolizers: limit caffeine to 1-2 cups, no afternoon caffeine\"], \"slow_metabolizers\": \"1F allele — caffeine lingers, increased MI risk at high doses\", \"variant\": \"rs762551\"}"}